Terms And Conditions


Enter terms about covid compliance that we have considered.

Things you need to know

1.   The following are part of the contract between the exhibitor and/or sponsor and the congress managers, MCI Australia, and exhibitors/sponsors must observe these rules. In addition, any regulations imposed by the virtual platform must also be observed. Any areas not covered are subject to MCI’s final decision.

  • 1.1.   You (the sponsor/exhibitor) by returning a completed, signed and dated form explicitly accept these terms and conditions.
  • 1.2.   Details may change without notice. Please refer to the congress website for the latest information.
  • 1.3.   MCI Australia (ABN 76 108 781 988) representing the organising committee and the Host body does not accept responsibility for any errors, omissions or changes.
  • 1.4.   You agree that the organisers and other authorised stakeholders may use your contact information for any relevant purpose such as administration or advising of future events. You may ask us to limit communication to necessary matters.
  • 1.5.   The Platform and MCI do not take responsibility should internet connection become unstable. Internet connection is out of the control of MCI Australia and the Platform provider, it is the responsibility of the delegate/sponsor/stakeholder to have stable connection to access the platform.
  • 1.6.   We will use reasonable endeavours to provide constant, uninterrupted access to the Platform and the Services, but with any software product, this cannot be guaranteed. We will not be responsible or liable for any direct or indirect losses or damages suffered or sustained by you as a result of, or in connection with, any interruption or delay in accessing and using the Platform or the Services
Use of the platform

2.   You will not, and you will ensure the Authorised Users will not:

  • 2.1.   Modify the platform or merge any aspects of the platform with another programme other than as expressly provided under this Agreement.
  • 2.2.   Record, reverse engineer, copy, duplicate, reproduce, create derivate works from, frame, download, display, transmit or distribute any of the Platform, the source code of the Platform or any documents, manuals or setup instructions provided with the Platform or in relation to the Services
  • 2.3.   License, sell, rent, lease, transfer, assign or otherwise commercially exploit the Platform or the Services
  • 2.4.   Engage in unlawful behaviour, including unauthorised access to or use of data, services, systems or networks, including an attempt to probe, scan or test the vulnerability of a system or network or to break security or authentication measures
  • 2.5.   Access, store, distribute or transmit:
    • 2.5.1.   Viruses, work, trojan or other malicious code that corrupts, degrades or disrupts the operation of the Platform;
    • 2.5.2.   Material that is unlawful, unethical, harmful, threatening, defamatory, obscene, infringing, harassing or racially or ethnically offensive or a contravention of the rights of any third party;
    • 2.5.3.   Material that facilitates illegal activity, or
    • 2.5.4.   Material that abuses or causes damage or injury to any person or property
  • 2.6.   Provide Platform login details or password, or otherwise provide access to the Platform, to any unauthorised or unregistered third party and you will take all reasonable steps to prevent unauthorised access to, or use of, the Platform;
  • 2.7.   Share any features of the Platform that are not publicly available with any unauthorised third part; and
  • 2.8.   Engage in any conduct on the Platform that is in breach of this Agreement (or any agreements mentioned therein)
  • 2.9.   Any breach of this clause 1 constitutes a breach of this Agreement and we may, at our absolutely discretion, terminate or suspend your access to, and/or use of, the Platform or the Services, and/or take further actions against you for breach of this Agreement.

3.   Services

  • 3.1.   All Services will be provided based on the information and specifications supplied by you. All information that we provide is supplied in good faith, but we do not warrant or guarantee the accuracy or completeness of any information provided by us or any third party. It is not within the scope of our obligations to enquire as to, or to verify, the accuracy of completeness of information that we receive from your or any third parties.
  • 3.2.   The Services, Deliverables and any Platform functionality specified in previous conversations are indicative only and may be amended by us from time to time. While we will use all reasonable endeavours to deliver the features and functionality specified therein, nothing in this Agreement prevents us from amending the Services at any time during the event delivery.
  • 3.3.   We will use reasonable endeavours to provide the Services promptly or by an applicable Delivery Date or such other dates as agreed by the parties in writing. Any Delivery Date or time quoted for delivery, commencement or completion of any part of the Services is an estimate only and time will not be of the essence.
Your obligations

4.   Your obligations

  • 4.1.   You acknowledge that our ability to be able to provide the Platform and the Services to you without delate or interruption is dependent on your full and timely cooperation. You will (and will ensure that the Authorised Users will)
    • 4.1.1.   Co-operate with and assist us in the supply of your Platform content;
    • 4.1.2.   Promptly provide us with full and accurate information, data and explanations as and when required;
    • 4.1.3.   Comply with applicable laws and regulations (including the General Data Protection regulation (“GDPR”) with respect to user privacy, data collection, data retention, data transmission, data storage and the use of cookies
    • 4.1.4.   Comply with all reasonable directions and guidelines from us as advised from time to time.
Financial facts

5.   We will have no liability for any losses suffered or any damage caused by errors or omissions in any information or instructions provided to us by you in connection with the Platform, the Services or any actions taken by as at your direction.

  • 5.1.   In no event will MCI Australia/APLAR be liable to you or any third party for any:
    • 5.1.1.   Loss of profits, revenue, goodwill or business, business interruption, corruption, loss or alteration of data, downtime costs, loss of use, failure to realise anticipated savings or for any indirect or consequential loss of damage of whatsoever nature, however caused;
    • 5.1.2.   Viruses worm, trojan or other malicious code introduced into, or transmitted to, your or any third part during the course of using the Platform or the Services;
You and your staff

6.   Your application to sponsor or exhibit does not constitute an attendee registration. You will need to do that separately as per the information provided in the manual.

  • 6.1.   Your staff (even if entitled to a complimentary registration) will be denied access to the event or exhibition unless they have completed the relevant registration form.
Exhibitor notes

7.   Exhibitor notes

  • 7.1.   You have a limited licence to exhibit. You may not assign, share, sub-let, or grant registrations for the whole or part of the booth without our prior approval.
  • 7.2.   We are the sole judge of acceptable display items and you will remove them promptly if asked.
  • You will be responsible for any reasonable costs should contents of your exhibition need to be changed, removed or updated.
  • 7.3.   You and your staff must be attired and behaved in accordance with the professional atmosphere of the event.

Daniel Aletaha

Daniel Aletaha is Chair of Rheumatology and Head of the Division of Rheumatology at the Medical University of Vienna. Dr. Aletaha has received academic degrees from the Medical University in Vienna, Duke University and Danube University, and had spent over two years at the National Institutes of Health in Bethesda, Maryland. He is a dedicated scientist with broad interests in outcomes research, clinical trials, and translational research in inflammatory rheumatic diseases. He is author on more than 240 publications, and serves on the Editorial Board of several rheumatology specialty journals.

Daniel Aletaha has been involved in several International Task Forces, including EULAR Management Guidelines for RA and PSA, and the Treat-to-Target recommendations, and was lead author of the 2010 Classification Criteria for RA. He has served many years in the EULAR Executive and is currently treasurer of EULAR.

Andrea Low

Andrea Low

Singapore General Hospital


Microbiome in Systemic Sclerosis

Dr Andrea Low is Head and Senior Consultant in the Department of Rheumatology and Immunology, Singapore General Hospital. Her clinical and research interest is in systemic sclerosis (SSc). She spear-headed the nation-wide collaborative SSc research workgroup dedicated to advancing clinical care and research in SSc, and established the Systemic Sclerosis Cohort in Singapore (SCORE) since 2008. She is recipient of several awards including the National Medical Research Council Transition Award and Clinician Scientist Award for her work in SSc. She has garnered $3.8 million in grant funding and published extensively in this area. She is convenor of the APLAR systemic sclerosis/myositis special interest group, and member of the Scleroderma Clinical Trials Consortium.

Shingo Nakayamada

Shingo Nakayamada

University Of Occupational And Environmental Health


Immunophenotyping in Systemic Lupus Erythematosus

March 1996: Graduated from School of Medicine, University of Occupational and Environmental Health, Japan

June 1996: Joined the First Department of Internal Medicine, University of Occupational and Environmental Health, Japan for clinical training

March 2004: Completed doctoral program of disorder mechanism system and pathological mechanism section, Graduate School of Medical Science, University of Occupational and Environmental Health, Japan

April 2004 Assistant Professor, First Department of Internal Medicine, Hospital of the University of Occupational and Environmental Health, Japan

April 2007 Occupational Health Physician, Kobe Shipyard & Machinery Works, Mitsubishi Heavy Industries

April 2007 Part-time Researcher, Division of Cell Physiology, Department of Physiology and Cell Biology, Kobe University Graduate School of Medicine

October 2009 Visiting Fellow, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, U.S.A.

April 2012 Assistant Professor, First Department of Internal Medicine, Hospital of the University of Occupational and Environmental Health, Japan

January 2021 Associate Professor, First Department of Internal Medicine, Hospital of the University of Occupational and Environmental Health, Japan

Ran Nakashima

Ran Nakashima

Kyoto University Hospital


Novel therapeutic approaches: current clinical trials

1996-2002 Faculty of Mdicine, Kyoto University
2005-2010 Rheumatology and Clinical Immunology, Graduate school of Medicine, Kyoto University

2012-Present Assistant Professor, Rheumatology and Clinical Immunology, Kyoto University Hospital
2010-2012 Clinical fellow, Rheumatology and Clinical Immunology, Kyoto University Hospital
2003-2005 Resident in Shizuoka General Hospital
2002 Resident in Kyoto University Hospital

Japan College of Rheumatology
The Japanese Society of Clinical Immunology
The Japanese Society of Inflammation and Regeneration
The Japanese Society of Internal Medicine

Takako Miyamae

Takako Miyamae

Tokyo Women’s Medical University



Dr. Takako Miyamae is an Associate Professor in Pediatric Rheumatology, Institute of Rheumatology, Tokyo Women’s Medical University in Tokyo, Japan. She is also the president of this year’s Annual Meeting of the Pediatric Rheumatology Association of Japan.

Blank Circle

Dennis McGonagle

United Kingdom

Pathogenesis and therapy with rheumatic drugs in COVID

Justin Mason

Justin Mason

Imperial College London

United Kingdom

Imaging of large vessel vasculitis

Justin Mason was the recipient of Arthritis Research UK (ARUK) Intermediate and Senior Clinical Research Fellowships. He was appointed Professor of Vascular Rheumatology at Imperial College in 2009, Head of Vascular Sciences in 2017, Head of the Cardiovascular Division of the National Heart and Lung Institute in 2018 and Co-Director of the Imperial College Centre of Vasculitis Research Excellence in 2020. He has served as Chair of the ARUK Research and Capacity Committee and on the British Society for Rheumatology Heberden Committee. His basic science research focuses upon the relationship between vascular endothelial dysfunction and systemic inflammatory diseases, and he has a specialist clinical research interest in the investigation and management of the large vessel vasculitides including Takayasu arteritis.

Takashi Maehara

Takashi Maehara


IgG4-related disease: Immunological insights into the pathogenesis

I am activity involved in research on the pathogenesis of human autoimmune disorders especially the study of the immunological and epigenetic basis of Sjogren’s syndrome, IgG4-related disease, and systemic sclerosis. We have explored the immunology and epigenetic induction of clonally expanded disease-linked CD4+ T cells and B cells in the pathogenesis of IgG4-related disease and systemic sclerosis. Clonally expanded CD4+ T cells with a killer phenotype may cause inflammatory fibrosis in a number of clinical contexts.

I completed my DDS training at Kyushu University in 2007. Then I earned my Ph.D. in Clinical Immunology at Kyushu University in 2012. And I worked on cellular and molecular immunology at Ragon Institute of MGH, MIT and Harvard from 2015 to 2018.

Currently I am Assistant Professor, Section of Oral and Maxillofacial Oncology, Division of Maxillofacial Diagnostic and Surgical Sciences, Faculty of Dental Science, Japan.

Pedro Machado

Pedro Machado

University College London

United Kingdom

EULAR COVID-19 database and EULAR COVAX Database

Dr Pedro Machado, MD, PhD, FRCP, is an Associate Professor and Consultant Rheumatologist at University College London (UCL), University College London Hospitals (UCH) and Northwick Park Hospital, United Kingdom. He is a Principal Investigator at the UCL Centre for Rheumatology and at the UCL Department of Neuromuscular Diseases. His research interests include the assessment and prediction of outcomes in rheumatic diseases, with a focus on axial spondyloarthritis, myositis and COVID-19. He has published >155 peer-reviewed articles.

Dr Machado is the past-chair of the European Alliance of Associations for Rheumatology (EULAR) Standing Committee on Epidemiology and Health Services Research (SCEHSR). He is a member of the EULAR Research Committee, the COVID–19 Global Rheumatology Alliance (GRA) Steering Committee, the EULAR COVID-19 Registry steering group, Assessment of Spondyloarthritis International Society (ASAS), British Society of Spondyloarthritis (BRITSpA), International Myositis Assessment and Clinical Studies Group (IMACS), Muscle Study Group (MSG), British Society of Rheumatology (BSR), and the Portuguese Society of Rheumatology (SPR).

Vidya Limaye

Vidya Limaye

Royal Adelaide Hospital


Necrotising Myopathies: Update

Vidya Limaye is a staff specialist Rheumatologist in the Department of Rheumatology at the Royal Adelaide Hospital. After completing her rheumatology training she undertook a PhD in the Vascular Biology Laboratory at the Hanson Institute studying the role of sphingosine kinase in inflammation and angiogenesis. She has since established the South Australian Myositis Database; this is a large repository of over 900 patients with myositis which has enabled the study of clinical, epidemiological and immunogenetic aspects of inflammatory myopathies. She has a particular interest in myositis-specific autoantibodies and in the increasingly recognised subgroup of patients with necrotising myopathy.


Sue-Ann Ng

Singapore General Hospital


Update on APLAR systemic sclerosis project

Dr Sue-Ann Ng is a Consultant in the Department of Rheumatology and Immunology, Singapore General Hospital. She has a keen interest in clinical and research work in systemic sclerosis.

Masataka Kuwana

Masataka Kuwana

Nippon Medical School


Dr. Masataka Kuwana is a professor of rheumatology and a director of scleroderma/myositis center of excellence at Nippon Medical School in Tokyo, Japan. Dr. Kuwana has published more than 410 peer-reviewed scientific articles and written more than 10 book chapters. He is listed as an editorial board member of 7 peer-reviewed journals, and serves as an Editor-in-Chief of Modern Rheumatology and the Journal of Scleroderma and Related Disorders. Dr. Kuwana is considered an internationally recognized leading expert in systemic sclerosis, myositis, pulmonary hypertension, interstitial lung disease, and autoimmunity.

Ichiro Kobayashi

Ichiro Kobayashi

KKR Sapporo Medical Center


Interstitial lung disease in juvenile dermatomyositis in Asia

Dr. Ichiro Kobayashi graduated from Hokkaido University School of Medicine in 1984. After 5 years of clinical training as a pediatrician, he was engaged in the study of interleukin-6 receptor at Osaka University (Prof. T. Kishimoto’s Lab), and autoantibodies particularly associated with primary immunodeficiencies such as IPEX syndrome at Hokkaido University Hospital. In parallel with laboratory works, he has published clinical articles on pediatric rheumatic diseases such as juvenile dermatomyositis and pediatric Sjogren’s syndrome. He is now working at KKR Sapporo Medical Center as a Chief Pediatrician, and at Hokkaido University as a Visiting Professor.

Mitsumasa Kishimoto

Mitsumasa Kishimoto

Kyorin University School Of Medicine



He is currently serves as an associate professor at Kyorin University School of Medicine.

After completing the first training in Japan, he completed an Internal Medicine Residency program at the University of Hawaii, and a Rheumatology Fellowship program at New York University. In 2006 he took the role of Program Director of the Department of Rheumatology at the Kameda Medical Center, then from 2009 to 2019, clinical program director in St Lukes International hospital before moving on to accept his current positions in 2019.

Dr Kishimoto was certified by the American Board of Internal Medicine and Rheumatology and received an ACR Distinguished Fellow Award in 2006.

He was a Steering committee member in the ‘APLAR guidelines for management of rheumatoid arthritis and is currently SIG member in Spondyloarthritis. He also serves as a Steering committee member in JCR guidelines for management of RA and SpA in Japan.

He is a GRAPPA and ASAS member, and Japan’s Principal Investigators for the ‘ASAS-Comospa and perSpA’ studies.

Dr Kishimoto is an author of over 90 scientific publications including NEJM and Lancet articles.

Mitsuhiro Kawano

Mitsuhiro Kawano

Kanazawa University


IgG4-related kidney disease and IgG4-related periaortitis/retroperitoneal fibrosis

Mitsuhiro Kawano is a Japanese rheumatologist who is currently the director and associate professor of the Department of Rheumatology at Kanazawa University Hospital. He received the M.D. degree from Kanazawa University in 1987, and the Ph.D. degree in 1993. He is actively involved in routine patient care, teaching and research in rheumatology. He has been the first president of the Japanese Association of IgG4-Related Disease since September, 2019, and helped to publish the first English-language textbook on IgG4-related disease as a co-editor with Professor John H. Stone of Harvard Medical School in 2012. Recently, the ACR/EULAR IgG4-RD Classification Criteria Working Group has published international classification criteria for IgG4-related disease, and he took part in the working group as a core member.

Yutaka Kawahito

Yutaka Kawahito

Kyoto Prefectural University of Medicine


Post Marketing Surveillance and JCR guideline

Yutaka Kawahito, MD, PhD, is a professor of the Kyoto Prefectural University of Medicine and head of the Department of Inflammation and Immunology. He graduated from the Faculty of Medicine, Shimane University, and obtained his PhD from the Kyoto Prefectural University of Medicine in 1995. He was a research fellow at NIAMS of NIH from 1995 to 1998, and has been engaged in clinical and research at Kyoto Prefectural University of Medicine since 2000. He has been involved in numerous rheumatoid arthritis activities including a chairperson of a subcommittee of treatments for rheumatoid arthritis of JCR and a member of Modern Rheumatology editorial board.

Latika Gupta

Latika Gupta

Sanjay Gandhi Postgraduate Institute Of Medical Sciences


Conducting research online

Dr Gupta is a rheumatologist, clinical immunologist, and clinician scientist working as Assistant Professor at SGPGI, a tertiary care teaching hospital in Lucknow, India. She currently serves as the Social Media Editor for several Rheumatology journals and is the APLAR (Asia Pacific League of Associations for Rheumatology) Young Rheumatology Webmaster and Board Member from India.

She is a dedicated researcher (136 publications, H index 12, I index 19) with an interest in myositis, spondyloarthritis and digital health. She recently founded Myositis India, a patient support group for patients with this disease.

Besides enjoying medical teaching Dr Gupta enjoys amateur photography, poetry, and photo painting.

Takahisa Gono

Takahisa Gono

Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine


Update on APLAR myositis project

Name: Takahisa Gono
Business Address: Department of Allergy and Rheumatology,
Nippon Medical School Graduate School of Medicine
1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8603, JAPAN
Business Phone: +81-3-3822-2131
Business Fax: +81-3-5814-6024
E-Mail Address:
Birth Date: October 4th,1973
Birth Place: Tokyo, Japan
Citizenship: Japan

2004, Ph.D, Shinshu University Graduate School
1992-1998, Yamanashi University, Yamanashi, Japan, M.D. 1998

2016-Present Associate Professor, Department of Allergy and Rheumatology, Nippon Medical
School Graduate School of Medicine
2015-2016 Associate Professor, Department of Rheumatology, Saitama Medical Center, Jichi
Medical University
2014-2015 Associate Professor, Institute of Rheumatology, Tokyo Women’s Medical University
2007-2014 Assistant Professor, Institute of Rheumatology, Tokyo Women’s Medical University
2004-2007 Assistant Professor, Third department of Internal Medicine (Rheumatology and Neurology), Shinshu University
2001-2003 Research fellow, Third department of Internal Medicine (Rheumatology and Neurology), Shinshu University

Councilor of The Japanese College of Rheumatology
Councilor of The Japanese Society of Clinical Immunology
Editorial Board, BioMed Research International Journal

2002 The Japanese Society of Internal Medicine
2006 The Japanese Society of Neurology
2006 The Japanese College of Rheumatology

2012 Young Investigator’s Award of the Japanese Society of Rheumatology
2013 Young Investigator’s Award of the Japanese Society of Internal Medicine

Peter Nash

Peter Nash

Griffith University, Brisbane


Head-to-head Study Evaluating Secukinumab versus Adalimumab in Psoriatic Arthritis Patients (EXCEED): Efficacy on ACR Components, Remission and Patient Reported Outcomes

Peter Nash is Professor in the School of Medicine at Griffith University, Queensland, and Director of the Rheumatology Research Unit on the Sunshine Coast. Prof. Nash has Chaired the Professional Affairs Committee and the Therapeutics Committee, the NHMRC musculoskeletal panels and serves on the Scientific Advisory Committee of the Australian Rheumatology Association. He is a former member of the Therapeutics Committee of the Australia and New Zealand Bone and Mineral Society. He remains on the International Steering Committee for GRAPPA. He is on the editorial board of Annals of the Rheumatic Diseases and RMD Open.

Prof. Nash and his group at the Rheumatology Research Unit have been involved with pivotal registration clinical trials for all modern targeted biologic therapies and osteoporosis therapies. He has published more than 200 peer-reviewed papers and 5 book chapters and was recently recognized as rheumatology citation leader top 20 rheumatology journals over the last 5 years. His special interests include metabolic bone disease and novel therapeutics.

Elena Nikiphorou

Elena Nikiphorou

King’s College Hospital & King’s College London

United Kingdom

The use of social media among rheumatologists: reality vs perspectives

Consultant Rheumatologist at King’s College Hospital & Adjunct Senior Lecturer at King’s College London. Clinical and academic interest in inflammatory arthritis.

Philip Conaghan

Philip Conaghan

University Of Leeds

United Kingdom

Update on future therapeutics in OA treatment

Professor Philip Conaghan MBBS PhD FRACP FRCP is Director of the Leeds Institute of Rheumatic and Musculoskeletal Medicine (a EULAR Centre of Excellence) at the University of Leeds and Deputy Director of the NIHR Leeds Biomedical Research Centre. His research focuses on understanding pathogenesis and developing effective therapies for common arthritis and joint problems. He is an executive member of the international outcomes group OMERACT. He has previously chaired UK NICE osteoarthritis clinical guidance, is co-editor of the Oxford Textbook of Rheumatology and has authored/co-authored over 600 publications as original research, reviews and book chapters.

Laila Girgis

Laila Girgis

St Vincent’s Hospital Sydney And University Of New South Wales


Autologous Haematopoietic Stem Cell Transplantation For Systemic Sclerosis Results In Improved Clinical Outcome Measures Including Survival

Dr Laila Girgis is the Head of the Rheumatology Department and Senior Staff Specialist at St Vincent’s Hospital, Sydney. She is a Senior Lecturer (Conjoint) at the University of New South Wales, in the St Vincent’s Clinical School. She is co-supervising a PhD at the St Vincent’s Centre for Applied Medical Research, and also conducts medical teaching and clinical research.

Marie Gene Cruz - Invited Speaker

Marie Gene Cruz

Philippine College Of Physicians


Dr. Cruz is a graduate of Internal Medicine residency training program of the Philippine General Hospital. She is currently a diplomate of the Philippine College of Physicians. She is interested in public health, health policy and clinical epidemiology.

Arvind Chopra - Chairperson

Arvind Chopra



Arvind Chopra is the founding Director and Chief Rheumatologist at Centre for Rheumatic Diseases, Pune India. Besides practise, he is a physician scientist with over 150 research publications and a mentor and teacher for training fellowship program in rheumatology and PhD. His main research domains are epidemiology, chikungunya, drug trials and Ayurvedic medicines. He was appointed ILAR COPCORD coordinator in 2005 and currently is is APLAR COPCORD coordinator since 2017. He was made the first master by the Indian Rheumatology Association in 2019. He is the international fellow of the American College of Rheumatology since 1998 and a honorary fellow of the Royal College of Physicians London since 2017.

Chi-Chen Chang

Chi-Chen Chang

Taipei Medical University


Professor Chang Chi-Chen, MD and PhD, Taipei Medical University, is a rheumatologist. He is Head of the Department of Rheumatology in Taipei Medical University Hospital. His research interests are in the ultrasound in rheumatic diseases. He serves on the editorial boards of IJRD and is the Secretary General of APLAR. He is also the boards of Director of Taiwan Rheumatology Association.

Sharon Bout-Tabaku - Invited Speaker

Sharon Bout-Tabaku

Sidra Medicine


Dr. Bout-Tabaku is Division Chief of pediatric rheumatology and Assistant Professor of Clinical Pediatrics at Weill Cornell Medical College _ Qatar. She has been practicing pediatric rheumatology for the past 14 years in the US and now in Qatar.

She was a fellowship program director and a researcher in the US.

She received funding through the Rheumatology Research Foundation, Arthritis Foundation, the Columbus Medical Research Foundation, the Nationwide Children’s Hospital Research Institute.

Currently her research involves characterizing the genetics and function of rare autoimmune and autoinflammatory diseases, and the pharmacogenomics of TNF inhibitors.

Khalid Alnaqbi - Chairperson

Khalid Alnaqbi

Tawam Hospital

United Arab Emirates


❖ Dr. Khalid Alnaqbi is currently a Consultant and Chief of Rheumatology (Tawam Hospital, UAE), Physician Lead of Rheumatology Committee of SEHA Medical Council, and Vice President of Emirates Society for Rheumatology.
❖ Clinical Professor, UAE University
❖ Examiner for the Arab Board of Internal Medicine
❖ Faculty of Internal Medicine residency programs at Tawam Hospital.
❖ Graduated from the College of Medicine and Health Sciences, UAE University.
❖ Completed post-graduate residency training at the University of Toronto in Internal Medicine, Rheumatology, and Spondyloarthritis Fellowship.
❖ Holds multiple board certifications (American and Canadian Boards in Internal Medicine and Rheumatology, Clinician Investigator Board, Patient Safety and Quality Improvement Program).
❖ Published in peer-reviewed journals and wrote a book chapter on (Diagnosis of Ankylosing Spondylitis). Dr. Alnaqbi is a journal reviewer in prestigious journals.
❖ Fellow of the American College of Physicians (FACP), a Fellow of the American College of Rheumatology (FACR), and a Fellow of the Royal College of Physicians & Surgeons of Canada (FRCPC).
❖ Member in the Assessment of Spondyloarthritis international Society (ASAS), and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA).
❖ Member of Mohammed Bin Rashid Academy For Scientists
❖ Speaker in numerous national and international meetings.

Vikas Agarwal - Invited Speaker

Vikas Agarwal

Sanjay Gandhi Postgraduate Institute of Medical sciences

Lucknow, India

Prof. Vikas Agarwal

Did his graduation in 1991 and postgraduation in 1996 in Internal Medicine from King George’s Medical College, Lucknow, India and fellowship in Clinical Immunology from Sanjay Gandhi postgraduate Institute of Medical Sciences, Lucknow in the year 2000. He joined the department of clinical Immunology and Rheumatology as assistant professor in 2004 after a brief stint as Senior Lecturer in Medicine at Government Medical College and hospital, Chandigarh. Presently he is professor and has published more than 300 papers and 10 book chapters.

Current areas of interest are : Vasculitis,
Scleroderma and other fibrotic conditions,
Mechanisms of drug resistance,
Tropical Rheumatology (Tuberculosis and Leprosy)



Get in quick, early bird registration expiries in:

  • 00Days
  • 00Hours
  • 00Minutes
  • 00Second
  • 00D
  • 00H
  • 00M
  • 00S
Keishi Fujio

Keishi Fujio

University of Tokyo


Integrated functional genome analysis of immune-mediated diseases

1995 M.D. Medical School, University of Tokyo

1998-2000 Department of Hematopoietic Factors, Institute of Medical Science, Graduate
School of Medicine, University of Tokyo

2000-2002 Department of Allergy and Rheumatology, Graduate School of Medicine, University of Tokyo

2001-2002 Postdoctral Fellowship of Japan Society for Promotion of Science

2002-2005 Research Resident of Japan Association for Preventive Medicine

2006- 2013 Assistant Professor, Department of Allergy and Rheumatology,
Graduate School of Medicine, University of Tokyo

2013- Lecturer and Deputy Director, the Department of Allergy and Rheumatology, University of Tokyo Hospital

2017- Professor and Director, the Department of Allergy and Rheumatology, University of Tokyo Hospital

Babur Salim

Babur Salim

Pakistan Society for Rheumatology(PSR)



Associate Professor of Rheumatology
Fauji Foundation Hospital Rawalpindi

Hajime Yoshifuji

Hajime Yoshifuji

Kyoto University


Genetic and immunological mechanisms of large-vessel vasculitis

Since 2000, Dr. Yoshifuji has been engaged in the treatment and research of patients with autoimmune diseases, especially Takayasu arteritis (TAK), IgG4-related disease, and relapsing polychondritis (RP) at Kyoto University. Since 2013, he has made important contributions in genomic study and clinical trials for Takayasu arteritis. He also contributed to the composition of Japanese treatment guidelines for vasculitidis revised in 2017 as the prime secretariat manager. Currently, he is an Associate Professor/Lecturer at Dept. of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University. He is dedicated to supporting two Japanese patient associations for TAK and RP.

Motohisa Yamamoto

Motohisa Yamamoto

The Institute of Medical Science, The University of Tokyo


Topics on advanced clinical practice for IgG4-related dacryoadenitis/sialadenitis and autoimmune pancreatitis

Dr. Motohisa Yamamoto is a rheumatologist, belonging to The Institute of Medical Science, The University of Tokyo since 2019. The theme of his research is the pathological elucidation and development of new treatments for IgG4-related disease. Until now, he has been mainly engaged in clinical research on IgG4-related disease. He contributed the separation and the independence of Mikulicz’s disease (IgG4-related dacryoadenitis and sialadenitis) from Sjögren’s syndrome. Next, He was involved in the development of the comprehensive diagnostic criteria, 2011. He and his colleagues established the registry for the patients with IgG4-related disease, a SMART registry, and they announced several important findings in clinical practices. He firstly reported that standardized incidence ratio of malignancies in IgG4-related disease was significantly increased. He now tries to challenge the omics analysis in IgG4-related disease.

Chris Wincup

Chris Wincup

University College London

United Kingdom

Social media for Rheumatology Practice

Having qualified from Brighton & Sussex Medical School in 2009 with MBBS and 1st Class (hons) BSc in Biomedical Sciences I began my post-graduate medical training in North West London where I was awarded an Academic Foundation Post allowing me to undertake research at the Kennedy Institute of Rheumatology (Charing Cross Hospital). I undertook Core Medical Training based at Northwick Park, Hammersmith and Charing Cross Hospitals during which I gained membership to the Royal College of Physicians.

In 2013, I began specialist post-graduate training in the field of Rheumatology and General Internal Medicine. Since October 2016 I have been working as a Clinical Research Fellow exploring abnormal iron metabolism and mitochondrial dysfunction in systemic lupus erythematosus (SLE) at University College London. I have been funded by LUPUS UK and UCLH Charity in addition to being awarded the Versus Arthritis (formerly Arthritis Research UK) Clinical Research Fellowship that is funding my PhD work. In 2018 I was awarded the Kovac’s Travelling Fellowship by the Royal Society of Medicine to spend time working at the Rheumatology Department at Northwestern Hospital, Chicago (USA) where I formed a research collaboration.

I hold membership of a number of profession organisations including acting as Rheumatology Trainee Representative to the Royal Society of Medicine. I am the British Society for Rheumatology (BSR) BRiTs representative for North Central / East London. Since 2018 I have been a member of the EULAR-EMEUNET Working Group.

Hisanori Umehara

Hisanori Umehara

Nagahama City Hospital



Dr. Umehara is a vise president, Nagahama City Hospital. He is a Rheumatologist with wide knowledge of Clinical and Basic Immunology. Dr. Umehara has been a professor and chairman, Kanazawa Medical University, and served as the Japanese director of Sjögren’s International Collaborative Clinical Alliance (SICCA) during 2006 to 2014, and a chairman of All Japan IgG4-RD team by Health, Labor and Welfare, Japan (2011-2013). He has published many papers on IgG4-related disease including comprehensive diagnostic criteria for IgG4-RD, 2011.

Yoshiya Tanaka

Yoshiya Tanaka

University of Occupational and Environmental Health



Yoshiya Tanaka, MD, PhD is Professor and Chairman of the First Department of Internal Medicine, School of Medicine (2000-present) and Dean of Graduate School of Medical Science (2017-present), University of Occupational and Environmental Health, Japan. He reviewed >740 publications in English (impact factor >3600, h-index 88). His scientific focus lies on pathological mechanism and development of novel treatment in rheumatic diseases and osteoporosis. He was a president of JSBMR in 2013-15. He is a chair of scientific committee of APLAR, chair of international committee of JCR, president of JACI. He received numerous awards from JSBMR, JCR and EULAR.

Sakae Tanaka

Sakae Tanaka

The University Of Tokyo



Sakae Tanaka MD, PhD graduated from University of Tokyo in 1987. He learned osteoclast biology in Department of Biochemistry, Showa University School of Dentistry from 1990 to 1993 and worked as a postdoctoral associate in Department of Cell Biology, Yale University School of Medicine from 1993 to 1995. He has been serving as Professor in the Department of Orthopaedic Surgery, Faculty of Medicine, the University of Tokyo since 2012. He has more than 500 international publications, 50 international presentations in international congresses and more than 15,000 citations in indexed international scientific journals with h-index 58. His clinical specialty is joint surgery and clinical interest includes rheumatoid arthritis and osteoporosis. His scientific fields of interest are osteoclast biology, signal transduction and apoptosis.

Katsuya Suzuki

Katsuya Suzuki

Keio University


Molecular Understanding Of Remission In Rheumatoid Arthritis: A Concept Of Molecular Remission

Dr. Katsuya Suzuki is a rheumatologist, Assistant Professor of Rheumatology, Department of Internal Medicine, School of Medicine, Keio University in Tokyo, Japan. He is also a councilor of Japan College of Rheumatology and The Japan Society for Clinical Immunology. His major research interests are pathogenesis, translational research and clinical studies/trials for autoimmune diseases including rheumatoid arthritis, systemic lupus erythematosus, vasculitis, Sjogren’s syndrome, and IgG4-related syndrome.

Leonila Dans

Leonila Dans

St Vincent’s Hospital Sydney And University Of New South Wales


Autologous Haematopoietic Stem Cell Transplantation For Systemic Sclerosis Results In Improved Clinical Outcome Measures Including Survival

Dr Laila Girgis is the Head of the Rheumatology Department and Senior Staff Specialist at St Vincent’s Hospital, Sydney. She is a Senior Lecturer (Conjoint) at the University of New South Wales, in the St Vincent’s Clinical School. She is co-supervising a PhD at the St Vincent’s Centre for Applied Medical Research, and also conducts medical teaching and clinical research.

Matthew Brown

Matthew Brown

King’s College London

United Kingdom


Matt Brown is a clinician-scientist who trained initially in medicine and rheumatology in Sydney, Australia before completing a Doctorate of Medicine based at University of Oxford, focusing on genetics of ankylosing spondylitis. He was appointed Professor of Musculoskeletal Sciences at University of Oxford in 2004. In 2005 Matt returned to Australia, firstly to University of Queensland, and since 2016, at Queensland University of Technology, where he was Professor and Director of Genomics. In 2013 he was elected to Fellowship of the Australian Academy of Sciences in recognition for his achievements in genetics research. In 2019 he moved to King’s College London and Guy’s and St Thomas’ Hospitals NHS Trust to direct their NIHR Biomedical Research Centre.

Debashish Danda



Astellas logo

Sales Operation Area Management Support, Japan Commercial, Astellas Pharma Inc.

AWR logo

Association of Women in Rheumatology

AWIR is a global organization with more than 11,000 touchpoints and 8 global chapters/partners worldwide. AWIR’s mission is to promote the science and practice of Rheumatology, foster the advancement and education of women in Rheumatology, and advocate access to the highest quality health care, and the management of patients with Rheumatic diseases.

CSF Logo

Cesas Medical

The Cytokine Signalling Forum (CSF) is an educational website developed under the auspices of the University of Glasgow and is dedicated to the dissemination of the latest developments in cytokine signalling. It provides continuing medical education to clinicians around the globe to facilitate greater understanding of the science of cytokines and cytokine signalling, and its implications for clinical practice.

UCB logo

UCB Biopharma SRL

UCB is a global biopharmaceutical company focused on the discovery and development of innovative medicines. Our ambition is to transform the lives of people living with severe diseases, with a focus in immunology and neurology.

GSK Logo


We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. We have three global businesses that research, develop and manufacture innovative pharmaceutical medicines, vaccines and consumer healthcare products.

Daiichi-Sankyo logo

Daiichi Sankyo Co., Ltd.

Chugai logo

Chugai Pharmaceutical Co., Ltd

Chugai Pharmaceutical is one of Japan’s leading research-based pharmaceutical companies with strengths in biotechnology products. As an important member of the Roche Group, Chugai is actively involved in R&D activities in Japan and abroad. Specifically, Chugai is working to develop innovative products which may satisfy the unmet medical needs.

Boehringer Ingelheim logo

Boehringer Ingelheim

Making new and better medicines for humans and animals is at the heart of what we do. Our mission is to create breakthrough therapies that change lives. Since its founding in 1885, Boehringer Ingelheim is independent and family-owned. We have the freedom to pursue our long-term vision, looking ahead to identify the health challenges of the future and targeting those areas of need where we can do the most good.

As a world-leading, research-driven pharmaceutical company, more than 51,000 employees create value through innovation daily for our three business areas: Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. In 2019, Boehringer Ingelheim achieved net sales of

19 billion euros. Our significant investment of almost 3.5 billion euros in R&D drives innovation, enabling the next generation of medicines that save lives and improve quality of life.

We realize more scientific opportunities by embracing the power of partnership and diversity of experts across the life-science community. By working together, we accelerate the delivery of the next medical breakthrough that will transform the lives of patients now, and in generations to come.

More information about Boehringer Ingelheim can be found at or in our annual report:

Asahi Kasei Logo

Asahi Kasei Pharma Corporation

Asahi Kasei Pharma discovers, develops, manufactures, and delivers prescription drugs in the fields of orthopedics, circulatory, urology, the immune system, and the central nervous system.

Pharmaceuticals from Asahi Kasei Pharma include Teribone™ for osteoporosis and Elcitonin™ Injection 20S for osteoporosis pain, the Recomodulin™ anticoagulant, each of which has a competitive position in its respective market.

Kevzara® is a human monoclonal antibody that blocks the action of interleukin-6 (IL-6) by binding to IL-6 receptors, for the indication of rheumatoid arthritis in patients who have had an inadequate response to conventional treatments.

Kevzara® is a registered trademark of Sanofi Biotechnology.

The product information is intended for general information purposes. The names, descriptions, and labeling of approved products are of Japan origin.

Product availability, names, indications, and presentations may vary from country to country.

Pfizer. Japan Inc

At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines. Our diversified global health care portfolio includes human biologic and small molecule medicines and vaccines, as well as many of the world’s best-known consumer products.

Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as the world’s leading biopharmaceutical company, we also collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us.

Novartis logo

Novartis Pharma K.K.

Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. We consistently rank among the world’s top companies investing in research and development.

Gilead logo

Gilead Sciences K.K.

Gilead Sciences is a biopharmaceutical company that discovers, develops, and commercializes innovative therapeutics in areas of unmet medical need. Gilead’s Inflammation R&D team is focused on improving therapeutic options for the treatment of multiple inflammatory conditions through a comprehensive clinical trial program evaluating novel agents with the goal of advancing patient care.

Bristol Myers Squibb logo

Bristol Myers Squibb K.K.

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

Abbvie logo


AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow.

We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio.

Lilly logo

Eli Lilly Japan K.K.

Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work.

Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism.


Janssen, a division of Johnson & Johnson

At Janssen, we’re creating a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension.

Janssen Asia Pacific is one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

LG Chem logo

LG Chem

LG Chem, the leading chemical company, has strengthened market dominance starting from the Basic Materials & Chemicals business to Energy Solution, IT and Electronic Materials and Life Science area.

Life Sciences Company focuses at four major healthcare services including pharmaceutical, vaccine, medical device and biopharmaceutical.

Based on its own fundamental technology, LG Chem expanded its pipeline to include biosimilars in order to improve patient access to highly effective biological products.

LG Chem will continue to improve the quality of life by providing innovative portfolio of medicines across the world.

Janssen logo

Janssen Pharmaceutical KK & Mitsubishi Tanabe Pharma Corporation

At Janssen, we’re creating a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension.

Janssen Asia Pacific is one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

Christine Bernal

Christine Bernal

University Of Santo Tomas


Cytokine Targeted Therapy for Pediatric Rheumatic Diseases in the Philippines

Dr. Bernal is a pediatric rheumatologist who, after her residency training in pediatrics in the University of Santo Tomas Hospital, pursued her fellowship training in rheumatology in Baylor College of Medicine, Houston, Texas. While training abroad, she was a recipient of several prestigious awards including Drs. Ralph and Judith Feigin Resident Award of Excellence, American College of Rheumatology (ACR) outstanding fellow award and ACR Amgen Pediatric Rheumatology Research Award. Her research works on lupus, Kawasaki, polyarteritis nodosa and juvenile idiopathic arthritis has been published in international journals including Arthritis and Rheumatism, International Journal of Rheumatic Diseases and APLAR Journal of Rheumatology. She also authored a chapter on Juvenile idiopathic arthritis for Arthritis and Allied Conditions (a textbook in Rheumatology) in 2005 & a chapter on Disorders of Bones & Connective Tissues for Fundamentals of Pediatrics in 2014.

A graduate of UST Faculty of Medicine and Surgery, she now serves her alma mater as Associate Professor. At present, she is the section chief of Pediatric Rheumatology in UST Hospital and Cardinal Santos Medical Center; an active medical consultant in a number of private tertiary hospitals in Metro Manila.

Sandra Navarra - Circular Speaker Image - 500px x 500px

Sandra Navarra

University of Santo Tomas Hospital


B-directed therapies

Prof. Sandra Navarra is head of Rheumatology at University of Santo Tomas Hospital, Manila, and active consultant in Rheumatology at St. Luke’s Medical Center, Quezon City, Philippines. She served as Secretary-General, head of Education Committee, and chaired the SLE special interest group of Asia Pacific League of Associations for Rheumatology (APLAR). She was past-president of Philippine Rheumatology Association and is currently CEO of Rheumatology Educational Trust Foundation Inc. (RETFI) which oversees the Applied Rheumatology Made Simple (ARMS), Lupus Inspired Advocacy (LUISA) and People Empowerment for Arthritis and Lupus (PEARL) programs. Prof Navarra is a member of the Lupus Academy Steering Board, and founding-executive board member of both Asia Pacific Lupus Collaboration (APLC) and Asian Lupus Nephritis Network (ALNN).

Sang Cheol Bae

Sang Cheol Bae

Hanyang University

South Korea

SLE genomics

Sang-Cheol Bae is a Full Professor (1993~) and Distinguished Professor (2012~) of the Hanyang University; the former Director of the Hanyang University Hospital for Rheumatic Diseases (2005-2019); Director of Hanyang University Institute for Rheumatology Research (2019~), Seoul, Korea and the elected president of 15th International Congress on SLE (2023). His illustrious career shows excellent leadership as a medical service provider as well as a clinical and translational researcher in SLE and RA.
Professor Bae acquired his MD in 1984, and subsequently a PhD in 1993, from the Hanyang University, Seoul, Korea. From 1996 to 1998, he worked as a rheumatology research fellow and instructor at the Brigham and Women’s Hospital, Harvard Medical School, Boston, USA. In 1998, he also obtained a MPH from the Harvard School of Public Health, Boston, USA.
Professor Bae’s major research interests include

  1. Clinical epidemiology including clinimetrics, clinical trials and innovative treatment development, clinical and pharmaco-economics, and outcomes research;
  2. Genetic epidemiology including drug discovery and repurposing;
  3. Precision medicine, in the field of rheumatic diseases, particularly SLE and RA. He has published ~ 700 articles on these topics in national and international peer-reviewed journals.
Thaschawee Arkachaisri

Thaschawee Arkachaisri

KK Women’s and Children’s Hospital


Cytokine targeted therapy for Pediatric Rheumatic Diseases in Singapore

Dr. Tash graduated from Mahidol University, Thailand in 1991. He then pursued his specialty and subspecialty training in the US and earned his American Board of Pediatrics, Allergy and Immunology and lastly, Pediatric Rheumatology at Cornell University prior to returning back to Thailand and established the first Pediatric Rheumatology department at Siriraj Hospital and Mahidol University in January 2001. He then moved back to the US and joined Children’s Hospital of Pittsburgh where he gained his research interest in scleroderma and established the first Pediatric Scleroderma clinical and research Program in 2006. Then, he developed the Localized Scleroderma Cutaneous Assessment Tool which is the well-accepted clinical assessment measures in Localized Scleroderma and has been well-accepted as the standard assessment worldwide.

In 2009, he then moved back to Singapore to established its first Pediatric rheumatology clinical program and in 2011, the Asia-Pacific Pediatric Rheumatology Education and Research Network. Over the decades, he has published the epidemiologic and outcomes of children with rheumatic diseases in Singapore and Southeast Asia. He also actively involved in pediatric rheumatic diseases translational researches in trying to better understand the underlying immune-mechanisms and predict outcomes. He is currently an Associate Professor, head and senior consultant at the Rheumatology and Immunology Department at KK Women’s and Children’s Hospital and Duke-NUS Medical School.

Yannick Allanore

Yannick Allanore

Paris Descartes University


Is disease modification possible?

Yannick Allanore is Professor of Rheumatology at the Paris Descartes University in Paris since 2008. Professor ALLANORE is the Head of a research group working on the cardio-pulmonary aspects of systemic sclerosis and other chronic inflammatory rheumatic diseases through clinical research programs and basic research ones, including genetic and cellular biology approaches, and also an animal model platform covering various models of inflammatory driven fibrosis (INSERM U1016, Cochin Institute).

He has published over 430 papers in peer-review journals. Professor Allanore is a member of several professional bodies, including the French Rheumatology Society and the American College of Rheumatology. He is the former elected chairman (2013-2019) of the The EUROPEAN Scleroderma Trials and Research group (EUSTAR). He is member of the Steering Committee of the World Scleroderma FOUNDATION, he was the chairman of the programme of the 2020 world scleroderma congress.

Amita Aggarwal

Amita Aggarwal

Sanjay Gandhi Postgraduate Institute of Medical sciences Lucknow


Cytokine targeted therapy for Rheumatic diseases in children in India

Amita Aggarwal is a Professor and Head of Clinical Immunology and Rheumatology at the Sanjay Gandhi Postgraduate Institute, Lucknow, India. She completed her medical education at All India Institute of Medical Sciences, New Delhi. She subsequently trained in Clinical Immunology & Rheumatology at SGPGI, Lucknow, Later, she trained at Royal Melbourne Hospital, Melbourne, Center’s for disease control, Atlanta, USA and Oklahoma university hospital, Oklahoma, USA in Immunology & Rheumatology.

She is a clinician scientist, with major interest in Juvenile arthritis and SLE. She has setup a multi-institutional lupus network in India. In addition, she has taught a generation of physicians working in the field of rheumatology. In recognition of her work, she has been elected fellow of the Indian academy of Science, National academy of Science as well as National academy of Medical Sciences. She has also served as the President of Indian Rheumatology Association as well as editor of Indian Journal of Rheumatology.

Lai Shan - Circular Speaker Image - 500px x 500px

Lai-shan Tam

The Chinese University Of Hong Kong

Hong Kong

Axial psoriatic arthritis- is it different from axial spondyloarthritis?

Lai-Shan Tam, MD, is Division Head and a Professor in the Division of Rheumatology within the Department of Medicine and Therapeutics at The Chinese University of Hong Kong. She has been serving as the Chairperson of the International Affair Committee of APLAR since 2012.

She was President of the Hong Kong Society of Rheumatology from 2011 to 2014, and Vice President of APLAR from 2014-2016. In addition, Professor Tam was a member of the International Task Force Subcommittee of ACR, the EULAR Programme Committee from 2016-2019, and EULAR honorary member (since 2019). She serves as the Associate Editor of International Journal of Rheumatic Disease, and also as members of the editorial boards in a number of journals including Rheumatology, Frontiers in Medicine and the Latin American Journal of Psoriasis and Psoriatic Arthritis, and she is also the international advisory board member of the Lancet Rheumatology.

She is the first author or co-author of over 200 articles published in major rheumatology journals. Her research interests include premature atherosclerosis and bone loss in patients with rheumatic diseases.

Seto - Circular Speaker Image - 500px x 500px

Yohei Seto

Department Of Rheumatology, Tokyo Women’s Medical University Yachiyo Medical Center


Ultrasound and its clinical use in Crystal induced arthritis

Dr Yohei Seto is an associate professor in Rheumatology Department, Tokyo Women’s Medical University Yachiyo Medical Center. He is a former member of Japan College of Rheumatology (JCR) Ultrasound Standardization Committee. He had also involved in organizing standardized ultrasonography educational courses on behalf of JCR, and in establishing 2020 Japanese practice guideline for rheumatoid arthritis on behalf of Japanese Ministry of Health, Labour and Welfare and 2018 Japanese guideline for gout and hyperuricemia on behalf of Japanese Society of Gout and Uric & Nucleic Acids.

Kenji Oku - Circular Speaker Image - 500px x 500px

Kenji Oku

Hokkaido University Graduate School Of Medicine


Prevention of infective complications in SLE for the APLAR consensus statements

Kenji Oku is an associate professor of the Department of Rheumatology, Endocrinology and Nephrology at the Hokkaido University Graduate School of Medicine. His interests have focused on both basic science and clinical research in SLE and the antiphospholipid syndrome.

Most recently, as the member of the standing committee of the APLAR, he and his colleagues published the Consensus Statements on the Management of SLE. Additionally, as fellow of Japan College of Rheumatology (JCR), he holds various senior level positions including the executive director of the standing committee of the Japanese clinical guidelines of SLE.

Eric Morand - Circular Speaker Image - 500px x 500px

Eric Morand

Monash University


Interferon inhibition

Professor Eric Morand graduated from Medicine at Monash University, trained in clinical rheumatology in Australia and at the Royal National Hospital for Rheumatic Diseases, UK and took his PhD at Monash University. His laboratory research focusses on glucocorticoid-induced proteins in the immune system, and his clinical research on systemic lupus erythematosus.

He founded the Lupus Clinic at Monash Health, and the Asia Pacific Lupus Collaboration, now the largest longitudinal cohort of SLE patients ever assembled. He chaired the 2017 International Congress on SLE, and awards include the William E Paul Distinguished Innovator Award of the Lupus Research Alliance, New York, Dean’s Award for Research Excellence, and the Parr Prize of the Australian Rheumatology Association.

CSF blue logo transparent 300x300 (ACR+APLAR)


The Cytokine Signalling Forum (CSF) is an educational website developed under the auspices of the University of Glasgow and is dedicated to the dissemination of the latest developments in cytokine signalling. It provides continuing medical education to clinicians around the globe to facilitate greater understanding of the science of cytokines and cytokine signalling, and its implications for clinical practice. Visit our website at or follow us on social media at links below
CC Mok - Circular Speaker Image - 500px x 500px

CC Mok

Tuen Mun Hospital

Hong Kong

APLAR consensus statements on the management of SLE

Chi-Chiu Mok is currently the chief of the Division of Rheumatology, Department of Medicine, Tuen Mun Hospital, Hong Kong. He is a consultant physician and honorary teaching professor of the University of Hong Kong and the Chinese University of Hong Kong.

An active researcher, Dr. Mok is the first author of more than 200 papers in a number of medical and Rheumatology journals that include the Annals of the Rheumatic Diseases, Nature Review Rheumatology, Arthritis and Rheumatology, Rheumatology (Oxford), and Arthritis Care & Research. His research interests include systemic lupus erythematosus, particularly lupus nephritis, and glucocorticoid induced osteoporosis. Dr. Mok is also the principal investigator of a number of phase II/III global trials investigating the safety and efficacy of novel biological agents in various rheumatic diseases.

Dr. Mok is currently the senior associate editor of the International Journal of Rheumatic Diseases and an editorial member of more than 10 medical journals that include the Journal of Rheumatology, Lupus, Current Rheumatology Review, Open Orthopedic Journal and Immunology and Immunogenetic Insights.

Dr. Mok is a Past President of the Hong Kong Society of Rheumatology. He is the founder editor of the Journal of Clinical Rheumatology and Immunology, the official publication of the Hong Kong Society of Rheumatology.

Iain Mclnnes - Circular Speaker Image - 500px x 500px

Iain McInnes

University of Glasgow

United Kingdom

The immune response to COVID-19 vaccinations in patients with impaired immune systems: the OCTAVE study

Iain McInnes is Vice Principal and Head of College of Medical Veterinary and Life Sciences, and Versus Arthritis Professor of Rheumatology in the University of Glasgow, Glasgow, United Kingdom. He is Director of the Versus Arthritis Centre of Excellence for Inflammatory Arthritis, lead from Glasgow that includes Universities of Oxford, Newcastle and Birmingham. He is immediate past chairman of the Foreum (Foundation for European Rheumatology Research) Scientific Committee, leads the European Roadmap programme that is defining the research agenda for European rheumatology for the next decade and is currently President of the European League Against Rheumatism (EULAR), the leading trans-national society for rheumatology across Europe.

Under these auspices he is creating the first pan-European Rheumatology Research Centre planning to launch in 2021. His work is mainly focused upon the understanding of the pathogenesis of immune mediated inflammatory diseases and encompasses basic discovery immunology through phase 1 and proof of concept experimental medicine clinical trials to leadership of pivotal phase 3 trials in the area of immune biology. His laboratory group performed original discovery work leading to the therapeutic targeting of a several inflammatory cytokines. More recently he has focused on the biology of myeloid cells in the pathogenesis of a number of immune diseases.

He has published >400 peer-reviewed original and review articles with an h-index of >100. He is a Fellow of the Royal Society of Edinburgh and Fellow of the Academy of Medical Sciences. He was made CBE in 2019 by HM Queen Elizabeth II.

Isao Matsumoto - Circular Speaker Image - 500px x 500px

Isao Matsumoto

Division Of Rheumatology, University Of Tsukuba


Recent topics of pathogenesis and therapy in rheumatoid arthritis

2002-2005 Researcher, PRESTO, Japan Science and Technology agency (An additional post)
2008- Associate Professor, Division of Rheumatology, Department of Internal Medicine, University of Tsukuba
2018- Deputy Director, Intractable Disease Medical Center, University of Tsukuba
2020- Director, Division of Rheumatology, Department of Internal Medicine, University of Tsukuba

2011 Novartis Prize for Rheumatology
2017 Prize from Japan College of Rheumatology

Ying Ying - Circular Speaker Image - 500px x 500px

Ying Ying Leung

Singapore General Hospital/ Senior Consultant.
Duke-nus Medical School/ Associate Professor.


New Grappa Recommendation

A/Prof. Ying Ying LEUNG is Associate Professor at Duke-NUS Medical School, and Senior Consultant of the department of Rheumatology & Immunology of Singapore General Hospital (SGH). She is currently the head of research in the department of Rheumatology and Immunology. Her research interests are in psoriatic arthritis and osteoarthritis, focusing in evaluation and development of measurement instrument and biomarkers.

A/Prof. Leung has been the Asian chair of the GRAPPA-OMERACT Outcome Measure working group, and serves in the education committee in the Group For Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). She led the peripheral arthritis domain working group in the GRAPPA recommendation update 2021.

Kong Kok Ooi - Circular Speaker Image - 500px x 500px

Kong Kok Ooi

Tan Tock Seng Hospital


Ultrasound and its clinical use in Psoriatic arthritis

Adj A/Prof Kong is the Head of the Department of Rheumatology, Allergy and Immunology Tan Tock Seng Hospital, Singapore. He established the first rheumatology ultrasonography service in Singapore in 2003 and since then has trained many other Rheumatologists in using ultrasound imaging as an aid in clinical practice.

David Karp - Circular Speaker Image - 500px x 500px

David Karp

American College of Rheumatology

United States

Progress in Systemic Lupus Erythematosus

Dr. David Karp is Professor and Chief of the Rheumatic Diseases Division at the University of Texas Southwestern Medical Center in Dallas, TX, where he holds the Harold C. Simmons Chair in Arthritis Research and the Fredye Factor Chair in Rheumatoid Arthritis Research. Dr. Karp’s recent investigation has focused on markers that predict development of disease in people at risk for systemic lupus erythematosus.

Dr. Karp has published over 100 research articles on rheumatology and immunology. He has received support for his research from the National Institutes of Health, the Lupus Research Alliance, the Arthritis Foundation and industry. Dr. Karp was President of the Rheumatology Research Foundation and is now President of the American College of Rheumatology.

Ori Eikayam - Circular Speaker Image - 500px x 500px

Ori Elkayam

Tel Aviv medical center


2019 Update of EULAR Recommendations for vaccinations in adult patients with autoimmune inflammatory RMDs

Professor Ori Elkayam is Head of the department of Rheumatology, at the Tel Aviv Medical Center. She has completed her studies of Medicine at the Tel Aviv University and her training in rheumatology at the Tel Aviv Medical Center.

She was the President of the Israeli Society of Rheumatology from 2011 to 2017 and has published more than 190 publications in leading journals of rheumatology.

Her main clinical fields of interest are vaccination in rheumatic diseases, spondyloarthritis and interventional rheumatology.

Prof. Elkayam is a leading researcher on the effect of vaccinations in autoimmune diseases, being the chair of the EULAR task aimed at formulating the EULAR recommendations for vaccination in auto-immune inflammatory diseases. She is one of the architect of the Israeli Registry of rheumatic patients treated with biologics.

Asami Abe

Niigata Rheumatic Center, Department of Rheumatology


Ultrasonography in the patients with rheumatoid arthritis treated by biological agents and Janus kinase inhibitor, the corresponding synovial histological findings

1985 4-1991 3 Asahikawa medical college
1991 4 Asahikawa medical college, Department of Orthopaedic surgery
1991 4-1999 3 Hospitals in Hokkaido, Department of Orthopaedic surgery
1999 4-2003 4 Asahikawa medical college, graduate school
2003 9-2004 7 Mount Sinai medical School, Human genetics, Postdoctoral Researcher
2004 7-2005 5 University of British Columbia, School of Dentistry, Postdoctoral Researcher
2005 6-2005 9 Asahikawa medical college, Department of Orthopaedic surgery
2005 10-2006 10 Niigata Prefectural Senami Hospital, Department of Rheumatology
2006 11- Niigata Rheumatic Center, Department of Rheumatology

Patricia Maria Gregoria Cuaño - Invited Speaker

Patricia Maria Gregoria Cuaño

Philippine College Of Physicians


Patricia completed her undergraduate degree in BS Biology at the University of the Philippines-Diliman, graduating summa cum laude. She then pursued a medical degree at the University of the Philippines-Manila, graduating cum laude. She then chose a path in Internal Medicine, completing her residency training at the Philippine General Hospital, where she also served as the Assistant Chief Resident for Research in 2020. She hopes to pursue a career in Endocrinology, with special interest in clinical nutrition, but at present, she is busy caring for her rambunctious two-year old daughter.

Atulya Deodhar - Plenary presentation

Atulya Deodhar

Oregon Health & Science University

United States

Atul A. Deodhar, MD, is Professor of Medicine and Medical Director of rheumatology clinics at the Division of Arthritis & Rheumatic Diseases in Oregon Health & Science University, Portland. He is Board Certified in Internal Medicine and Rheumatology; and is a fellow of the American College of Rheumatology, and also American College of Physicians.

Dr. Deodhar is a past-chair of SPARTAN (Spondyloarthritis Research and Treatment Network), an organization of North American Rheumatologists dedicated to education and research in the field of axial spondyloarthritis. He serves on the Steering Committee of GRAPPA (Group for the Research and Assessment of Psoriasis and Psoriatic Arthritis). He served on the American College of Rheumatology’s (ACR) treatment guidelines sub-committee, and as the associate editor of the Advanced Rheumatology Course by Association of Health Professionals in Rheumatology (ARHP). He has served the ACR in various other capacities as a vice chair of the annual meeting planning committee, member of the peripheral MRI task force, Association of Rheumatology Health Professionals (ARHP) nominating committee and developer of the ARHP online advanced rheumatology course. Dr. Deodhar serves on the Rheumatology Board of the American Board of Internal Medicine (ABIM)

Dr. Deodhar is the Editor-in-Chief of Best Practice and Research Clinical Rheumatology, and has been a guest editor for Current Opinion in Rheumatology. He is a reviewer for the New England Journal of Medicine, Lancet, Arthritis & Rheumatology, Annals of the Rheumatic Diseases, Annals of Internal Medicine, among several other journals. His research interests are axial spondyloarthritis, and psoriatic arthritis. He has authored 3 books, over 250 peer-reviewed articles; several book chapters, and editorials. Dr. Deodhar has been He has been a principal or co-investigator in more than 100 clinical trials, mostly focused on therapies for ankylosing spondylitis, psoriatic arthritis, and rheumatoid arthritis.

He completed his fellowship in rheumatology at Oregon Health & Science University, and before that, a research fellowship in rheumatology at the Royal Cornwall Hospital, Truro, England. He completed his residency in internal medicine and geriatrics at the Royal Cornwall Hospital, Truro, as well as in the Sassoon General Hospital and King Edward Memorial Hospital, Pune, India. He received his MBBS and MD degrees from the University of Pune, India; and the MRCP from the Royal College of Physicians, London, England.

Sandra Tankeh-Torres


Sulaiman Al-Mayouf - Invited Speaker (2)

Sulaiman Al-Mayouf

King Faisal Specialist Hospital & Research Center

Saudi Arabia

Consultant of Pediatric Rheumatology at King Faisal Specialist Hospital & Research Center (KFSH-RC), Riyadh and Professor at Medical College, Alfaisal University.

Dr. Al-Mayouf served as a board- member of Saudi Society for Rheumatology.

He is the national coordinator for the Pediatric Rheumatology International Organization (PRINTO).

Dr. Al-Mayouf authored numerous papers and reviews on pediatric rheumatology. In addition, he serves as a reviewer for several scientific journals. He is a frequent lecturing nationally and internationally in Pediatric Rheumatology.

Shahana Rahman

Bangabandhu Sheikh Mujib Medical University



Professor of paediatrics. Started Paediatric Rheumatology in Bangladesh as the pioneer. For more than last 15 years, practicing, teaching and training paediatric rheumatology.

Masaki Mori



Masaaki Mori is currently a professor within the Department of Lifetime Clinical Immunology, Graduate School of Medicine and Dental Sciences, Tokyo Medical and Dental University.
In addition to this he is an instructor at the Japan College of Rheumatology and a Japanese Pediatric Specialist.
He is also the Director of the Japanese Society of Clinical Rheumatology and Chairman/Direcotr of the Pediatric Rheumatology Association of Japan.

Jayathri Jagoda

CSRRSL (college Of Specialists In Rheumatology And Rehabilitation Sri Lanka)

Sri Lanka


Dr Jayathri Jagoda currently works in the premier paediatric hospital in Sri Lanka, Lady Ridgeway Hospital, Colombo.
Received APLAR fellowship grant in 2007.
Used to serve as the secretary and the treasurer of CSRRSL.
Member of specialty board in Rheumatology and Rehabilitation.
President of the Sri Lanka association for Child Development.

Observational study on using hyaluronic acid on Sri Lankan patients 2004
Audit on Drug survival of Leflunomide in Wellington regional Rheumatology unit, Newzealand 2007.
Leflunomide in clinical practice published in International Journal of Rheumatic Diseases 2011.
Disease activity scores in rheumatoid arthritis patients in District general hospital Gampaha, Sri Lanka. 2015

Aila Marnelle Cruz__ - Invited Speaker

Aila Marnelle Cruz

Philippine College Of Physicians


Aila Cruz is an internist from the Philippines. She obtained her undergraduate degree in BS Basic Medical Sciences under the Integrated Liberal Arts and Medicine Program of the University of the Philippines College of Medicine in 2015. She received her medical education under the same program, obtaining her Doctor of Medicine as cum laude in 2017. Afterwards, she took up her residency in Internal Medicine at the Philippine General Hospital, recently completing her training in 2020. She plans to pursue further training in Pulmonary Medicine and Critical Care.

Geraldine Zamora - Invited Speaker

Geraldine Zamora

Philippine Rheumatology Association


Dr. Geraldine Zamora is a fellow of the Philippine Rheumatology Association and heads its vasculitis SIG. She sits in the board of the Asia Pacific Young Rheumatologists, and is Vice President of the Hope for Lupus Foundation Philippines. She was awarded The Outstanding Young Men (TOYM) in 2016 & The Outstanding Women for the Nation’s Service (TOWNS) in 2019 for her contributions in the field of Medicine in the Philippines as a clinician, researcher, teacher and author. She also takes time to teach Filipinos on health literacy, and to inspire women to be empowered, on her social media pages. To know more, visit

Sumaira Farman - Invited Speaker

Sumaira Farman

National Hospital & Medical Center; Central Park Medical College; Fatima Jinnah Medical University(FJMU);ACF


MRCP (UK); Specialty Certificate Examination (SCE) Rheumatology (UK); International Fellow of American College of Physicians (FACP) & Rheumatology (FACR); Fellow Royal College of Physicians (FRCP) London; GradCertPRheum (Australia).
Primarily an adult rheumatologist, she interned in pediatric rheumatology, Kansas University Medical Centre, USA through an ACP International Fellowship; and acquired the Graduate Certificate in Paediatric Rheumatology (GradCertPRheum) from the University of Western Australia.
Based in Lahore, Pakistan, she is Professor and Head of Rheumatology Department National Hospital & Medical Centre, Visiting Faculty and Chair of the Paediatric Rheumatology program at Central Park Medical College.
She is Associate Editor IJRD.
She is Focal Representative Global Paediatric MSK Task Force, and Convener APLAR Paediatric Rheumatology SIG.
She is Immediate Past President, Pakistan Society for Rheumatology Co-Founder & Co-Chairperson Arthritis Care Foundation, Lahore.

Ghita Harifi

United Arab Emirates

Cary Amiel Villanueva_ - Invited Speaker

Cary Amiel Villanueva

Philippine College Of Physicians


Cary Amiel G. Villanueva, MD completed his residency training in internal medicine at the Philippine General Hospital in Manila. He received his medical degree through the Integrated Liberal Arts and Medicine (INTARMED) program of the University of the Philippines College of Medicine. Apart from working with the APLAR clinical practice guidelines on gout, he also served as an evidence reviewer for the Philippine COVID-19 Living Recommendations. Amiel’s interests include critical care, bioethics and evidence-based medicine. He also enjoys #MedTwitter (@caryamiel) and learning about health data science.

Benny Antony

University of Tasmania


Dr Antony is a senior research fellow at the Menzies Institute for Medical Research, University of Tasmania. He completed a degree in Medicine and a PhD in osteoarthritis research. His expertise includes clinical trials, novel MR imaging and biochemical markers, systematic reviews and Complementary and Integrative Medicines in osteoarthritis.

Dr Antony has published >70 research papers and a book chapter. His publications include top-tier journals such as JAMA, Lancet, Ann Intern Med and Ann Rheum Dis. He is an investigator for >10 clinical trials, supervise PhD and medical students.

He has received grants from competitive sources totalling >$1.5 million. He has received young investigator awards from >10 organisations (ASBMR, EULAR, APLAR, OARSI, ARA). He is a reviewer for >35 international journals, Special issue Editor of ‘Biomarkers’ and an Associate Editor of IJRD. He is a Young Investigator Committee member of the Osteoarthritis Research Society International (OARSI) and has given>20 oral presentations at the annual scientific meetings of the ACR, EULAR, APLAR, OARSI and Australian-New Zealand Rheumatology Conferences.

Md Mujibur Rahman - Invited Speaker

Md Mujibur Rahman

Bangabandhu Sheikh Mujib Medical University


Professor Md. Mujibur Rahman is a renowned Internist recently joined to BSMMU as the Professor of Internal Medicine after serving Dhaka Medical College Hospital (DMCH) as professor and Head of Medicine. Under the leadership of Prof Rahman, the COVID-19 unit of DMCH was the largest dedicated COVID-19 hospital in the country. He and his team ran different research project in DMCH including several clinical trials. He is also one of the investigators of the SOLIDARITY trial of WHO in Bangladesh. He served different public medical college as faculty and proved himself as a great teacher, researcher and a humanely physician.

For his deep interest in Rheumatology, he used to run a Rheumatology Clinic which is giving services to hundreds of patients each week. He was the Principal Investigator of ShSMCH site for an international drug trial on Lupus Nephritis. He was the principal investigator of first STEP-wise survey of NCDs risk factors in Bangladesh in 2010. He took leadership in managing Dengue and Chikungunya outbreak in Dhaka during the time of crises.

Prof. Md. Mujibur Rahman was born in Gazipur, near Dhaka, in the year 1961. He has a very brilliant academic career as well as professional one. He did his HSC in 1977 and HSC in 1979 with distinction and stood 11th position in the combined merit list of Dhaka Board from Dhaka Residential Model school and college. He graduated from Dhaka Medical College in the year 1985 and joined the Government service of and completed FCPS in Internal Medicine in 1992 and MD Internal Medicine in 2001. He was awarded with International Fellowship Exchange Program of American College of Physicians as a first Bangladeshi Physician and he worked in rheumatology department of Massachusetts General Hospital in the year 2006.
Along with taking care of admitted patients, he is extensively involved in teaching and training programs. In his colourful professional career of 35 years, he has an enormous number of students and followers in home and abroad. He has over 60 publications in national and international journals and he presented over 50 papers in national and international seminars.

He is currently elected councillor of BCPS and was Honorary Controller of Examinations of the Bangladesh College of Physicians and Surgeons (BCPS), which is the number one postgraduate institute of the country.
Currently Prof. Md. Mujibur Rahman is the vice president of Bangladesh Rheumatology Society, Bangladesh Society of Medicine and Association of Physicians of Bangladesh. He is a Fellow of the American College of Physicians. He is the editorial board member of Bangladesh Journal of Medicine. He is trying to engage himself in improvement in the medical education, physicians’ training and research in Bangladesh.

Blessie Marie Perez - Invited Speaker

Blessie Marie Perez

Philippine College Of Physician


Dr. Blessie Perez attended the University of the Philippines-Manila where she received her Bachelor of Science degree in Biology, graduating Magna cum laude last 2011. In 2016, she earned her medical degree from the College of Medicine of the same institution. Recently, she completed her Residency Training in Internal Medicine at the UP-Philippine General Hospital. Outside of medicine, she enjoys singing and watching dramas.

Prasanta Padhan - Invited Speaker

Prasanta Padhan

Kalinga Institute Of Medical Sciences, Kiit University

Bhubaneswar, Odisha, India. Pin: 751024

Professor, dept. of Clinical Immunology and Rheumatology, Kalinga Institute of Medical Sciences, Kiit university, Bhubaneswar, Odisha, India.

Greco Mark B Malijan - Invited Speaker

Greco Mark B Malijan

University of Oxford

United Kingdom

Greco is an internal medicine specialist and an MSc International Health and Tropical Medicine candidate at the University of Oxford. During his residency training in the Philippine General Hospital, he was involved in research understanding the issues in transition of care of patients from in-hospital to outpatient settings. At present Greco is working on his dissertation exploring the effects of long term and short term awareness of reported deaths on the transmission dynamics of COVID-19 in the Philippines.

Julie Li-Yu

Philippine Rheumatology Association


Associate Professor – University of Santo Tomas Faculty of Medicine and Surgery

Chief – Section of Rheumatology, UST FMS and Chinese General Hospital and Med Center

President – Osteoporosis Society of the Phils Foundation Inc

Immediate Past President – Phil Rheumatology Association

Head – PRA Osteoporosis Special Interest Group

Chin-Hsiu - Invited Speaker

Chin-Hsiu Liu

China Medical University Hospital


Dr. Liu is the Chief of Division of Translational Medicine in Rheumatology and Immunology Center, China Medical University Hospital, Taiwan. Her study interests focus on the stromal activation in the pathogenesis of syndesmophytes formation in AS. Her recent work published in Journal of Clinical Investigation delineated the importance of the unfolded HLA-B27-mediated activation of spliced X-box binding protein (sXBP) 1- retinoic acid receptor beta (RARB)- tissue non-specific alkaline phosphatase (TNAP) axis in AS syndesmophytes pathogenesis.

Ru Li - Invited Speaker

Ru Li

Peking Univeristy People’s Hospital


Ru Li is a professor of Department of Rheumatology and Immunology, People’s Hospital, Peking University. She is now serving as a youth committee member for Branch of Rheumatology, Chinese Medical Doctor Association, executive member of Rheumatology Branch of Chinese Information Association of Traditional Chinese Medicine, and executive editor of Rheumatology and Autoimmunity.  

Her research interests mainly focus on the etiology and the immunotherapy of rheumatoid arthritis. She has published over 60 articles on peer reviewed journals, e.g. Arthritis & Rheumatism, Rheumatology. She has also contributed to over 8 textbooks and book chapters in rheumatology.

Samar Al Emadi

Hamad medical corporation


Xenofon Baraliakos

Ruhr-University Bochum


Prof. Xenofon Baraliakos is the Head of Rheumatology at the Rheumazentrum Ruhrgebiet Herne and Professor for Internal Medicine and Rheumatology at the Ruhr-University Bochum, Germany.

He studied Human Medicine at the universities of Magdeburg and Berlin, Germany.

Prof. Baraliakos received his official Board Degrees in orthopaedic surgery in 2007 and in Internal Medicine and Rheumatology in 2014. His research interests are focused on the field of spondyloarthritides, with special emphasis on imaging outcomes and treatment.

Among others, Prof. Baraliakos won the EWRR Award, in 2005, the EULAR Young Investigator Award, in 2006 and 2008, the German patient’s AS Society Award in 2010 and the 2014 Award for Excellence in Clinical Research from the European Society for Clinical Investigations.

Prof. Baraliakos is the current President of ASAS (Assessment of Spondyloarthritis International Society). He holds membership of the American College of Rheumatology (ACR), the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) and the German Society of Rheumatology. He also acts as a reviewer and is an Associate Editor in a number of major rheumatological journals.

Aila Marnelle Cruz

Philippine College Of Physicians


Aila Cruz is an internist from the Philippines. She obtained her undergraduate degree in BS Basic Medical Sciences under the Integrated Liberal Arts and Medicine Program of the University of the Philippines College of Medicine in 2015. She received her medical education under the same program, obtaining her Doctor of Medicine as cum laude in 2017. Afterwards, she took up her residency in Internal Medicine at the Philippine General Hospital, recently completing her training in 2020. She plans to pursue further training in Pulmonary Medicine and Critical Care.

Tang Ching Lau

Singapore Society of Rheumatology


Dr Lau Tang Ching is currently working as a senior consultant rheumatologist in the Division of Rheumatology, University Medicine Cluster in the National University Health System. He has been appointed as the Vice Dean (education) of Yong Loo Lin School of Medicine, National University of Singapore in June 2017. He graduated in 1991 from the National University of Singapore and obtained his Membership of the Royal College of Physician in United Kingdom and the Master of Medicine (internal medicine) degree in 1997. He is a fellow of the Academy of Medicine Singapore since 2001. He also holds a Master of Medical Science degree in Clinical Epidemiology (University of Newcastle, Australia), and a graduate diploma degree in acupuncture (Singapore). His main research interests are in osteoporosis, pharmacoeconomic evaluation, medical education and evidence based medicine. He has helped to coordinate the Health Service Development Program for osteoporosis (HSDP) in 2003 to 2007 in the NHG cluster, which was successful in improving adherence and reducing the recurrent fracture rates of patients who were at high risk of recurrent fractures. He is helping to coordinate the Osteoporosis Disease Management Program (OPTIMAL), which is an extension of the previous HSDP osteoporosis program. He is currently the chairman of the National Arthritis Foundation. His hobbies include photography, singing, cooking, jogging and taichi.

Josef Smolen

Josef Smolen is Emeritus Professor of Medicine at the Medical University of Vienna, Austria. H received his MD degree from the University of Vienna, trained there in Immunology, Medicine and Rheumatology and was research fellow at the Arthritis Institute at the National Institutes of Health, Bethesda, MD, USA. 1989-2017 he was Chairman of 2nd Department of Medicine at Hietzing Hospital and 1995-2018 Professor of Medicine and Chairman of the Division of Rheumatology at Medical University of Vienna, where he also acted as Chairman of the Department of Medicine 3 2007-2018.

Major scientific interests concern the pathogenesis of rheumatic diseases, translational research, outcomes and epidemiologic research, and novel therapies and therapeutic strategies in rheumatic diseases. Basic research activities included mechanisms of T-cell activation and prevention of joint damage in arthritis. He developed clinical scores for rheumatoid, psoriatic arthritis and systemic lupus erythematosus. He led task forces for the elaboration of a number of management recommendations for several rheumatic diseases (RA, PsA).

Josef Smolen was President of EULAR from 2003 to 2005 and President of the Austrian Society of Rheumatology, Austrian Society of Immunology and Treasurer of the International Union of Immunological Societies. Dr Smolen is a member of the Austrian Academy of Sciences, the German Academy of Sciences (Leopoldina), Fellow of the Royal College of Physicians (London) and Honorary Doctor of Lund University (Sweden), Leiden University (The Netherlands) and Semmelweis University (Hungary). He is co-editor of “Rheumatology”, now in preparation of its 8th. He currently serves as editor-in-chief of Annals of the Rheumatic Diseases.

Hal Schofield

United States

Binoy Paul


Mikkel Ostergaard


Swapan Nath

United States

Durga Prasanna Misra

Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow


Dr Misra is an Associate Professor of Clinical Immunology and Rheumatology at SGPGIMS, Lucknow, a tertiary care teaching and research center in North India. His areas of research interest include vasculitis (particularly Takayasu arteritis), cardiovascular risk in rheumatic diseases, epidemiology of rheumatic diseases, systematic reviews and scientific writing and editing. He has published more than 200 papers in peer reviewed journals, as serves as an Associate Editor for Rheumatology International, Indian Journal of Rheumatology and JRCPE. He is the recipient of numerous awards, including the Indian Rheumatology Association Young Rheumatologist Oration 2019, Best Peer reviewer from Rheumatology International, Journal of Korean Medical Science, and International Journal of Rheumatic Diseases, as well as Publons Peer Review Award from 2017 to 2019.

Jose Paulo Lorenzo



Dr. Jose Paulo Lorenzo is a rheumatologist from the Philippines and the current Chief of the Section of Rheumatology in Makati Medical Center. He took his medical degree from UP College of Medicine and trained in Internal Medicine at UP-Philippine General Hospital. He took his fellowship in Rheumatology at UP-Philippine General Hospital and pursued his clinical and research fellowship in Rheumatology at Medical College of Wisconsin Affiliated Hospitals, USA. He was also a past president of the Philippine Rheumatologic Association.

Yuko Kaneko

Division Of Rheumatology, Department Of Internal Medicine, Keio University School Of Medicine


Yuko Kaneko is a Professor at the Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan. Prior to this appointment, she was Assistant Professor at the same University.

Prof Kaneko received her M.D. from the Keio University School of Medicine in 1997 and subsequently served as a Resident, Faculty and Instructor in Internal Medicine at Keio University. She was appointed as Assistant Professor at the Centre for Clinical Research in 2007, as Assistant Professor at the Rheumatology Department in 2019, and as Professor at the Rheumatology Department in 2021. She completed her PhD (Doctorate of Medical Science) in 2010 at the Keio University School of Medicine. From 2012-2013, she worked as a researcher at the Oxford University Nuffield Department of Orthopedics, Rheumatology and Musculoskeletal Sciences, UK.

She has published over 100 papers in peer-reviewed journals, with a focus on rheumatic diseases including rheumatoid arthritis, spondyloarthritis, Still’s disease, as well as IgG4-related disease.

Frank Beier

University of Western Ontario


Frank Beier is the Canada Research Chair in Musculoskeletal Research and the Chair of the Department of Physiology and Pharmacology at the University of Western Ontario. He is also a member of Western University’s Bone and Joint Institute. His lab explores mechanisms controlling cartilage and joint biology, both during skeletal development and in diseases such as osteoarthritis, using genome-wide gene expression studies and genetically modified mice for osteoarthritis research. For example, his research first implicated the EGFR pathway, several nuclear receptors, and the channel protein Pannexin 3 in this disease. Based on the identification of these pathways as mediators of osteoarthritis pathogenesis, several of his current projects attempt to translate these basic findings towards clinical applications.

Dr. Beier has published more than 140 peer-reviewed articles and gave more than 120 invited presentations across the world. His work is currently supported by a Foundation Grant from the Canadian Institutes of Health Research and funds from the NIH. He was a member of the Board of Directors of the Osteoarthritis Research Society International (OARSI) and is a current member of several editorial boards, including Deputy Editor for Osteoarthritis & Cartilage. He was the Chair of the 2017 Cartilage Gordon Conference and was awarded the Basic Science Award from OARSI in 2019. He served as standing member of the SBSR study section at NIH and currently is a standing member of the SBDD study section.

George Joseph

Christian Medical College


George Joseph is a professor of cardiology at the Christian Medical College in Vellore, India. His areas of interest include interventions in Takayasu arteritis, endovascular repair of aortic aneurysms and dissections and innovations in interventional devices and techniques. Professor Joseph has been published in over 100 indexed journals and was recently awarded the IJCTO Lifetime Achievement Award in 2016.

Rebecca James

Rebecca James

Queensland Children’s Hospital


Dr Rebecca James is a Paediatric Rheumatologist at Queensland Children’s Hospital. She undertook her training at the Royal Children’s Hospital (Melbourne) then completed an an extended fellowship at Great Ormond Street Hospital, London. She went on to complete an additional fellowship at the Evelina Children’s Hospital. Rebecca is the recipient of the Australian Rheumatology Association Leanne Stafford Award (2016) and the Great Ormond Street Junior Doctor of the Year Award 2016-2017. She is the Australian representative on the APLAR Paediatric Rheumatology Special Interest Group, and is also a member of the WHO Paediatric Musculoskeletal Task Force. In 2021 she completed a Healthcare Improvement Fellowship through Clinical Excellence Queensland and has an interest in patient engagement and improving the patient experience.

Blank Circle (1)

Judith James

United States

David Hunter

David Hunter

University of Sydney


Professor Hunter is a rheumatology clinician-researcher whose main research focus is clinical and translational research in osteoarthritis (OA). He is the Florance and Cope Chair of Rheumatology and Professor of Medicine at the University of Sydney and Royal North Shore Hospital. He is ranked as the leading expert in the world on osteoarthritis on and is the section editor for UpToDate osteoarthritis. He holds a medical degree and Master of Sports Medicine from the University of New South Wales, a fellowship in Rheumatology at the Royal Australian College of Physicians and earned a Masters of Medical Science (Clinical Epidemiology) from the University of Newcastle and received his PhD from the University of Sydney in 2001. He is an editor for leading international journals in his field, has authored books on osteoarthritis and has over 500 publications in peer-reviewed journals.

David D'cruz

David D'Cruz

Guys and St Thomas’ Hospital NHS Foundation Trust

United Kingdom

Professor D’Cruz is a member of this internationally renowned tertiary referral centre for autoimmune rheumatic disorders. His major clinical and research interests are systemic lupus erythematosus, the antiphospholipid syndrome and systemic vasculitis. He leads the Louise Coote Lupus Clinical Trials Unit which has a portfolio of investigator and industry led trials. His research portfolio includes a translational medicine programme in collaboration with basic science laboratories in the Division of Immunology, Inflammation and Infectious Diseases, Kings College School of Medicine. He has published widely and he is one of the Managing Editors of the journal Lupus. He is a past President of the Rheumatology Section of the Royal Society of Medicine.

Jeffrey Curtis

UAB Division of Clinical Immunology & Rheumatology

United States

Jeffrey R. Curtis, MD, MS MPH
Marguerite Jones Harbert – Gene V Ball, MD Professor of Medicine
Co-Director, UAB PharmacoEpidEmiology, and phaRmcoeconomics (PEER) Unit
Director, UAB Musculoskeletal Digital Health and Technology Laboratory
University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology

Dr. Jeffrey Curtis is a Professor of Medicine in the Division of Clinical Immunology and Rheumatology at the University of Alabama at Birmingham (UAB). Dr. Curtis received a Medical Degree (MD) and a Master of Public Health (MPH) degree from Oregon Health & Sciences University in Portland, OR. He subsequently completed a residency in internal medicine at Oregon Health & Science University and a fellowship in rheumatology at UAB. He completed a graduate program in Clinical Informatics at Stanford University and received his Master of Science (MS) degree in epidemiology at the Harvard School of Public Health. He is board certified in both rheumatology and clinical informatics.

Dr. Curtis holds the Harbert-Ball Endowed Professorship in Rheumatology and Immunology at UAB. His major research emphasis is on evaluating the safety and comparative effectiveness of medications for rheumatic diseases. He also conducts both investigator-initiated and industry-sponsored clinical trials in rheumatoid arthritis (RA) and psoriatic arthritis (PsA), including large pragmatic trials. He is the Co-Director of the UAB Pharmacoepidemiology and Pharmacoeconomics Research (PEER) Unit. PEER uses multiple large and linked data sources to study comparative effectiveness questions across multiple chronic diseases. The data sources he routinely uses include national electronic health record, health plan claims (e.g. Medicare, commercial insurance), traditional registry, patient reported outcomes, mobile device, wearable technology; he has done numerous projects that link these disparate data sources together. In 2012, he was awarded the Henry Kunkel Young Investigator Award by the American College of Rheumatology (ACR) and was accepted into the American Society for Clinical Investigation (ASCI) in 2016. In 2015, Dr. Curtis was appointed as a member to the FDA Arthritis Advisory Committee, and also the CDC’s ACIP Herpes Zoster Working Group.

The evaluation of the efficacy, comparative effectiveness, and safety of the medications, devices, and other interventions (e.g. vaccines) used in the care of rheumatoid arthritis, psoriatic arthritis, and spondyloarthritis patients. He served on the Core Expert Panel for the ACR’s 2008, 2012, and 2015 Recommendations for the Use of Nonbiologic and Biologic Disease Modifying Antirheumatic Drugs in RA. He was the Deputy Director for a collaborative project between the FDA, the Agency for Healthcare Research and Quality (AHRQ), and a number of academic centers studying the safety of biologic agents using multiple, pooled national data sources. He has served as the co-PI of the UAB Coordinating Center of the American College of Rheumatology’s (ACR) electronic health record-based registry Rheumatology Informatics System for Effectiveness (RISE) registry. RISE aggregates and normalizes EHR data from more than 3 million rheumatology patients, with data contributed by more than 1,000 rheumatology providers. He is the Co-PI of the mobile health-based, PCORI-funded Patient Powered Research Network “ArthritisPower” research registry, focused on RA, psoriasis, psoriatic arthritis, and Spondyloarthritis that has enrolled more than 30,000 patients.

Dr. Curtis also studies risk factors for and outcomes of osteoporosis. He was a member of the ACR’s task force to update recommendations for the management of glucocorticoid induced osteoporosis (GIOP). He served on the ASBMR Task Force on Atypical Subtrochanteric and Diaphyseal Fractures. In 2020, he was asked to serve on the ACR’s Vaccine Guideline Task Force, and he also leads the separate ACR COVID Vaccine Guidance Task Force.

Ved Chaturvedi

Sir Gangaram Hospital New Delhi


Prof Ved Chaturvedi after completing 35 years of service as rheumatologist in govt sector joined corporate teaching hospital in New Delhi India . Earlier he was heading dept of Rheumatology & Clinical immunology in resesrch & Referral Hospital of Govt of India in New Delhi.

He was first Rheumatologist in the country to establish MSK ultrasound , Medical ARTHOSCOPY & use of Biologics way back in 2002.

He was elected as president of Indian Rheumatology Association in 2009. He is past editor of Manual of Rheumatology an official publication of Indian Rheumatology Association . He was chairman scientific committee of last conference held by the Indian Rheumatology Association

He has been attending APLAR since last 20 years mostly as faculty

Sumapa Chaiamnuay

Thai Rheumatism Association and Thai Osteoporosis Foundation


Associate Professor Sumapa Chaiamnuay graduated from the faculty of Medicine, Chulalongkorn University, Thailand. She completed Internal Medicine residency training from Albert Einstein Medical Center, Philadelphia, and Rheumatology fellowship training from The University of Alabama at Birmingham. She served as the past secretary of the Thai Osteoporosis Foundation. Currently, she is the Chief of Thai Osteoporosis Foundation Public Relations, and the chief of the Rheumatic Disease unit at Phramongkutklao hospital. Her research interest is osteoporosis in rheumatic disease patients, and she’s on the working committee for the Thai Osteoporosis Clinical Practice Guideline 2021.

Helen Keen


Lorinda Chung_ - Invited Speaker

Lorinda Chung

Stanford University School of Medicine

United States

Dr. Lorinda Chung, MD, MS, is a Professor of Medicine (Immunology and Rheumatology) and Dermatology at Stanford University School of Medicine. She is the Director of the Scleroderma Program and Co-Director of the Multi-disciplinary Rheumatologic Dermatology Clinic with Dr. David Fiorentino. Dr. Chung is actively involved in clinical, translational, and epidemiologic research on systemic sclerosis and related connective tissue diseases. She is the principal investigator for multiple clinical trials of new potential therapies for scleroderma patients. She receives ongoing funding from the Scleroderma Research Foundation for the Stanford Scleroderma Center of Excellence. She is currently serving as the President for the international Scleroderma Clinical Trials Consortium.

Blank Circle

Lingli Dong

Department of Rheumatology and Immunology
Tongji Hospital
Huazhong University Of Science And Technology


Alireza Khabbazi - Chairperson

Alireza Khabbazi

Connective Tissue Diseases Research Center
Tabriz University of Medical Sciences

Tabriz, Iran

He was born in 1966 in Tabriz. He studied medicine at Tabriz University of Medical Sciences (TUOMS) from 1985 to 1992. He studied specialty in internal medicine at TUOMS from 1997 to 2001 and Subspecialty in rheumatology at Tehran University of Medical Sciences from 2003 to 2005. Now, he is working as a Professor in Internal Medicine group at medical faculty of TUOMS.

His positions are Head of the Connective Tissue Disease Research Center, Research deputy in Rheumatology ward, Research deputy in Internal Medicine group, member of Research Council of the Faculty of Medicine. His research interests are Behcet’s disease and other vasculitis, and palindromic rheumatism. He has 125 articles in English and has Scopus h-index = 16.

Blank Circle

Ashish Jacob Mathew

University of Copenhagen


Ida Ayu Ratih Wulansari Manuaba - Invited Speaker

Ida Ayu Ratih Wulansari Manuaba

Indonesian Rheumatism Association


I am an internist rheumatologist from Bali Indonesia and work in the internal medicine clinic of Prima Medica Hospital. In addition, I also lecture at the Bali International Unversity.
Worawit Louthrenoo - Chairperson

Worawit Louthrenoo

Chiang Mai University


Professor Worawit Louthrenoo is a rheumatologist at the Faculty of Medicine, Chiang Mai University, Thailand. He completed his Rheumatology Fellowships training at Mahidol University, Bangkok, Thailand in 1986, and at the University of Pennsylvania School of Medicine, USA, in 1991. His main interests are crystal-associated arthropathy, systemic lupus erythematosus, systemic sclerosis, rheumatoid arthritis and infectious arthritis.

Professor Louthrenoo serves in several professional associations executive committee, including APLAR. He has had over 80 book chapters and 150 journal articles published. He receives frequent invitations to speak at national and international rheumatology events. He has received many awards, including The Best Internist Award in 2010, Best Researcher Award from Chiang Mai University in 2011, Best Teacher Award in 2013, and recently The Dushdi Mala Medal from His Majesty the King Rama X in 2021.

Keith Lim - Chairperson

Keith Lim

Western Health, Melbourne University



Director of Rheumatology, Western Health , Melbourne,
Clinical Associate Professor , Melbourne University Dept of Medicine.
Research interests include clinical outcomes in Osteoarthritis and the role of inflammation and effusions ; and the role of biomarkers and cytokines in arthritis for eg RA, SpA and OA.

Jing Li - Invited Speaker

Jing Li

Peking Union Medical College Hospital


Dr. Li Jing, professor and chief physician of department of rheumatology and clinical immunology, Chinese Academy of Medical Sciences & Peking Union Medical College; National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology; State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital (PUMCH); Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education.
Major in management and research of systemic vasculitis, while practice with other common rheumatic disease, including SLE, RA, SpA, etc.

Caifeng Li - Invited Speaker

Caifeng Li

Beijing Children‘s Hospital


Doctor Caifeng Li is presently the director of the Department of Rheumatology and Immunology, Beijing Children’s Hospital, Capital Medical University, Ph.D., gratitude supervisor. She is a standing member of the Committee of the Chinese Society of Rheumatology and also standing member the Committee of the Beijing Society of Rheumatology.

She is the chairman of the Pediatric Branch of the Rheumatology Special Committee of the Cross-Strait Medical and Health Association. She is a member of the Chinese Academy of Pediatrics, a deputy secretary-general of the Chinese Academy of Pediatrics, and a deputy leader of the Immunology Group of the Chinese Academy of Pediatrics.

Besides, she is member of the Rheumatology Special Committee of the Chinese Medical Doctor Association, a member of the Rheumatology Special Committee of the Beijing Medical Doctor Association, and a member of the Paediatric Rheumatology International Trials Organisation (PRINTO).

Junichi Kikuta - Invited Speaker

Junichi Kikuta

Osaka University


Junichi Kikuta, M.D., Ph.D. graduated from Osaka University Medical School in 2006, and then worked as a physician specialized in rheumatology and internal medicine. He received his Ph.D. degree from Osaka University in 2013. He was an Assistant Professor at Osaka University from 2013 to 2019. He is currently an Associate Professor in the Department of Immunology and Cell Biology, Graduate School of Medicine and Frontier Biosciences, Osaka University.

His studies have so far elucidated the cellular dynamics in living bone tissues, with a special focus on bone-resorbing osteoclasts, by using intravital multiphoton-based bone imaging combined with pH-sensing chemical fluorescent probes that he has originally developed.

Kenji Kabashima

Kyoto University


Dr. Kabashima was born in Japan in 1970. He graduated from Kyoto University in 1996 and was trained in Medicine/Dermatology at the United States Naval Hospital in Yokosuka Japan, Kyoto University Hospital, and University of Washington Medical Center. He started research on bioactive lipid mediators at Kyoto University, which led to a PhD (under Prof. Shuh Narumiya). Then he studied at the Department of Dermatology, Kyoto University Graduate School of Medicine (Prof. Yoshiki Miyachi), UCSF (Prof. Jason Cyster), and University of Occupational and Environmental Health (Prof. Yoshiki Tokura). Currently, he is a chair/professor at the Department of Dermatology, Kyoto University Graduate School of Medicine, Japan, a principal investigator at the SRIS/SIgN, Singapore, and visiting consultant at the National Skin Centre, Singapore. His main interests include the mechanism of inflammatory skin diseases (atopic dermatitis, contact dermatitis, and psoriasis) and 3D-visualization of the skin using two-photon microscopy. His hobbies are marathon (sub 3hr), trail running (Ultra Trail du Mont Blanc 170 km), climbing, and travelling.

Blank Circle

Philip Mease

United States

Ahmadreza Jamshidi - Invited Speaker

Ahmadreza Jamshidi

Rheumatology Research Center
Tehran University of Medical Sciences


Ahmadreza Jamshidi was born in Iran 1961 in Iran. He studied medicine in 1988 and gave the internal specialized board in 1992And Rheumatology Board in 1996.He is currently a professor in the internal department of Tehran University of Medical Sciences and the president of Rheumatology Research Center. He has 188 scientific papers in Scopus with h-index 25. His research fields are COPCORD and Seronegative Spondylarthropaties.

Jun Ishizaki - Invited Speaker

Jun Ishizaki

Department of Hematology,
Clinical Immunology and Infectious Diseases
Ehime University Graduate School of Medicine


Jun Ishizaki, MD, PhD, is a designated lecturer at Department of Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine. He graduated from Ehime University Graduate School of Medicine, and obtained his PhD from Ehime University Graduate School of Medicine in 2016. His scientific field of interest is biomarker analysis in ANCA-associated vasculitis, large vessel vasculitis, and rheumatoid arthritis.

Annamaria Iagnocco - Plenary and Chair

Annamaria Iagnocco

University of Torino, Turin


Annamaria Iagnocco is Professor of Rheumatology and Head of the Academic Rheumatology Centre at Turin University, Italy. She is EULAR President. She is former Head of the EULAR School of Rheumatology, former co-chair of the OMERACT Ultrasound Group, Chair of the Ultrasound Study Group of the Italian Society for Rheumatology, member of several working groups on ultrasound in RMDs and faculty teacher in the EULAR Sonography Courses. Her research interests in RMDs include education, arthritis, and imaging. She is a member of the Editorial Board of prestigious international journals and has authored more than 290 peer-reviewed publications.

Pravin Hissaria - Invited Speaker

Pravin Hissaria

Royal Adelaide Hospital


Dr Pravin Hissaria is a Senior Clinical Immunologist at the Royal Adelaide Hospital, Immunopathologist at SA Pathology and a Senior Lecturer in the Adelaide University Department of Medicine. He is the Medical Director of COVID Vaccinations program at CALHN, Adelaide. He is a member of several national councils, working groups and advisory committees, including the Council of the Australasian Society of Clinical Immunology and Allergy (ASCIA), the Royal College of Pathologists Australia Immunopathology Advisory committee and the ASCIA Drug allergy working party. Dr Hissaria is a member of the Central Adelaide Local Health Network Drug and Therapeutics committee, the South Australian Medicines Evaluation Panel (SAMEP) and the Bellberry Ethics Committee, the largest private ethics committee in Australia. Dr Hissaria has received numerous research grants . He is the author of 64 peer reviewed publications and has an H-index of 14 (Scopus, May 2020).

Masayoshi Harigai - Chairperson

Masayoshi Harigai

Tokyo Women’s Medical University



Masayoshi Harigai, MD, PhD is Professor and Head of Division of Rheumatology, Department of Internal Medicine, Tokyo Women’s Medical University, Tokyo, Japan. He served as Professor of Department of Pharmacovigilance at Tokyo Medical and Dental University between 2007 and 2015 and has been installed in the present position in 2019. Professor Harigai is the principal investigator of Japan Research Committee of the MHLW for Intractable Vasculitis, clinical trial of tocilizumab for ANCA-associated vasculitis, and 2020 Japanese Clinical Practice Guidelines for the Management of Rheumatoid Arthritis. He has been serving as a board member of Japan College of Rheumatology since 2018.

Syed Atiqul Haq - Chairperson

Syed Atiqul Haq

BSM Medical University



Dr. SA Haq, Professor, Department of Rheumatology, Bangabandhu Sheikh Mujib Medical University (BSMMU) established the first Rheumatology Clinic of the country in October 1991. He was one of the co-founders of Bangladesh Rheumatology Society in 1997 and now is its Senior Vice President. In June 2000, as Chief Investigator, he founded the COPCORD Study Group in Bangladesh. The group has completed stage I COPCORD study and is carrying out stage II and III activities. He became Professor of Medicine (Rheumatology) in July 2001and Professor of Rheumatology in July 2006. He was awarded Fellowship of the Royal College of Physicians of Edinburgh in 2003 and International Fellowship of the American College of Rheumatology in 2005.

Dr. Haq’s areas of academic interest include Epidemiology of rheumatic disorders, knee OA and SLE. He has 188 publications in local and international journals out of which 104 are originals. He was awarded a Gold Medal by “Bangladesh Academy of Sciences” for contribution to the advancement of Science in the country. He has served Asia-Pacific League of Associations for Rheumatology (APLAR) in the capacities of APLAR-COPCORD (Community Oriented Program for Control of Rheumatic Disorders) coordinator, Vice President and Treasurer. Currently, Dr. Haq is holding the positions of President of APLAR.


Richard Furie

Northwell Health and Zucker School of Medicine at Hofstra/Northwell

United States

Dr. Richard Furie, Chief of the Division of Rheumatology at Northwell Health, is a rheumatologist whose activities for the last several decades have focused on patient care, physician education, and clinical research in the area of anti-rheumatic drug development. He directs The Program in Novel Therapeutics, the Health System’s clinical research program in musculoskeletal disease. 

He also directs the Hospital’s SLE and Autoimmune Disease Treatment Center, which has become internationally recognized for its role in the development of new therapies for SLE. Regarded as one of the senior rheumatologists in the New York metropolitan area, he has served as a volunteer for the local chapters of the Arthritis Foundation and the Lupus Alliance, the Lupus Foundation of America, the SLE Foundation, the Lupus Research Alliance, and Lupus Therapeutics. For twenty years he served on many committees of the American College of Rheumatology and was named a Master of the College in 2018. Although often featured as a speaker at national and international conferences, Dr. Furie’s favorite educational venue is at home with his colleagues and trainees.

Marco Matucci Cerinic - Invited Speaker

Marco Matucci Cerinic

Careggi University Hospital of Florence


Marco Matucci Cerinic MD, PhD, FRCP, FBSRhon, FACR
Professor of Rheumatology and Medicine, University of Florence, Florence, Italy
Scientific Consultant at IRCCS- Hospital San Raffaele, Milan, Italy
Marco Matucci-Cerinic is Full Professor of Rheumatology and Medicine at the Department of Ex-perimental and Clinical Medicine, Chairman of the IRB committee of the Tuscan region. Is a Scien-tific Consultant at Hospital San Raffaele. He works in the Rheumatology Division of the Careggi University Hospital of Florence. The professor is a member of the prestigious British Royal College of Physicians, the American College of Rheumatology, the Italian Society of Rheumatology and is an honorary member of the British Society of Rheumatology.

Dr Matucci-Cerinic has published more than 1300 peer review manuscripts widely in the field of rheumatology, particularly on the pathogenesis, clinical features and treatment of scleroderma, on spondyloarthritis and on osteoarthtritis. He has also served on various international and national committees_ in particular as EULAR General Secretary, as executive secretary of ILAR, as Chair-man of the European Scleroderma Trial and Research Group (EUSTAR) and vicepresident of the Scleroderma Clinical Trial Consortium (SCTC) . He is currently chairman of the World Scleroderma Foundation (WSF) and Editor in Chief of the Journal of Scleroderma & Related Diseases (JSRD) . He is also Associate Editor of Arthritis Research & Therapy and Clinical & Experimental Rheuma-tology, past Associate Editor and Co-Editor of Rheumatology. He serves on the boards of Annals of the Rheumatic Diseases, Rheumatology, Journal of Rheumatology, Scandinavian Journal of Rheu-matology and other rheumatology journals.

Carolyn Page

St Vincents Hospital


Carolyn Page is a senior musculoskeletal physiotherapist at St Vincent Hospital Melbourne. She has implemented many advanced scope physiotherapy roles at St Vincent’s including osteoarthritis, Rheumatology, and post hip and knee arthroplasty. She was a project lead in the development of the Victorian Model of Care for Osteoarthritis of the Hip and Knee in 2018 and is currently involved in developing a community based specialist clinic for osteoarthritis. She is involved in many research projects at St Vincent’s in physiotherapy and larger multidiscipline studies for hip and knee osteoarthritis.

Johannes Paolo B Cerrado

Philippine College Of Physicians


Dr. Cerrado is an internist from the Philippines with interests in evidence based medicine and global health. He has recently been involved in COVID-19 clinical research and related guidance on decision making and patient care.

James Wei - Chairperson

James Wei



Karl Phillip - Invited Speaker

Karl Phillip Avillo

Philippine College Of Physicians


Evidence reviewer for APLAR

Michael Holers

University of Colorado

United States

Following appointments as Assistant and then Associate Professor with tenure at Washington University in St. Louis, Dr. Holers was recruited to the University of Colorado (CU) to be the Smyth Professor of Rheumatology. In 2000, Dr. Holers became Division Head of Rheumatology at CU. The historical focus of the Holers Laboratory research efforts has been on the complement system structure-function relationships, biologic roles and therapeutic strategies.

More recently, Dr. Holers has moved a major focus to studying the preclinical pathogenesis of rheumatoid arthritis. To advance this area, he co-developed the SERA (Studies of the Etiology of Rheumatoid Arthritis) cohort. These collaborative studies have provided strong evidence for a mucosal origin of RA and identified candidate immune processes as therapeutic targets.

Ellen Gravallese

Brigham and Women’s Hospital; Harvard Med

United States

Ellen M. Gravallese M.D. is the Theodore Bevier Bayles Professor of Medicine at Brigham and Women’s Hospital, Harvard Medical School. She is Chief of Rheumatology, Inflammation and Immunity. Dr. Gravallese received her AB degree from Harvard College and her MD from Columbia University. She is board certified in anatomic pathology, internal medicine and rheumatology.

Dr. Gravallese’s basic science laboratory studies of the pathogenesis of inflammatory arthritis, with a particular interest in the impact of inflammation on bone. Her research has identified key molecular and cellular pathways in RA and contributed to the development of new therapeutic agents. She served as President of the American College of Rheumatology in 2019/20 and is an Associate Editor for New England Journal of Medicine.

Martin Aringer - Invited Speaker (1)

Martin Aringer

University Medical Center And Faculty Of Medicine TU Dresden


Martin Aringer, M.D., is Professor of Medicine, chief of the Division of Rheumatology and director of the interdisciplinary University Center of Autoimmune and Rheumatic Entities (UCARE) of the University Medical Centre and Faculty of Medicine at the TU Dresden, Dresden, Germany.

From 2003 to 2006 he was an Associate Professor of Medicine at Vienna Medical University, where he also received his Internal Medicine and Rheumatology training under Prof. Josef Smolen. From 1997 to 1999, Dr. Aringer joined the laboratory of Dr. John O’Shea at the National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, in Bethesda, MD, as a recipient of a Max Kade Postdoctoral Research. His main scientific focus are SLE and systemic sclerosis.

Su-Boon Yong - Invited Speaker

Su-Boon Yong

Lin Shin Hospital

Taichung, Taiwan, China


Dr Su-Boon Yong is the Consultant of Pediatrics, Division of Allergy, Immunology and Rheumatology at LIN SHIN Hospital. Dr Yong had wide-ranging research interests with primary focus on the safety of biological therapy for autoimmune diseases, childhood rheumatology diseases. Dr Yong has received several awards for his work, including Best abstract in (2017 ASPR, Hong Kong) and best oral presentation (2015 Taiwan). Dr Yong research interests include Juvenile idiopathic arthritis, Anaphylaxis, Urticaria, Asthma, and Atopic dermatitis. By the way, Dr Yong got particular interest in health education to the public.

Swan Sim Yeap

Subang Jaya Medical Centre



Dr Yeap is a Consultant Rheumatologist at Subang Jaya Medical Centre, Selangor, Malaysia. Her previous appointments include Associate Professor and Head of the Rheumatology Unit at the Department of Medicine, University of Malaya, Malaysia.

She is the current Vice-President, and a Past President, of the Malaysian Osteoporosis Society, a Past President of the Malaysian Society of Rheumatology, and was previously a Vice-President of the Asia-Pacific League of Associations for Rheumatology (APLAR), Asian Federation of Osteoporosis Societies (AFOS) and Persatuan SLE Malaysia.

She is currently the Chairperson of the Working Group for the 2022 Clinical Guidance on the Management of Osteoporosis, was the Co-Chairperson of the Working Group for the 2012 and 2015 Clinical Guidance on the Management of Osteoporosis.

Priscilla Wong - Chairperson

Priscilla Wong

Prince Of Wales Hospital

Hong Kong

Dr Priscilla Wong is the Associate Consultant of the Department of Medicine and Therapeutics at the Prince of Wales Hospital in Hong Kong. She is currently the Educational Co-chair of the APLAR Young Rheumatologists.

Binit Vaidya

National Center For Rheumatic Diseases


Dr Binit is a physician focusing his clinical and research work in rheumatology in Nepal since last 13years. Currently affiliated to National Center for Rheumatic Diseases (NCRD) at Gaushala, Kathmandu. Special interest lies in the field of early inflammatory arthritis, connective tissue disorders and osteoporosis. He has been undertaking nineteen researches and trials at his center and has more than 40 publications in various national and international journals to his credit.

Ester Penserga - Invited Speaker

Ester Penserga

Philippines General Hospital


She is Past President of the Philippine Rheumatology Association. She is Professor of Medicine in the University of the Philippines College of Medicine on Extension service, after retirement in 2020 and continues to serve in the Philippine General Hospital. She established the newest training program for Rheumatology in the East Avenue Medical Center in 2017, a government hospital under the Department of Health. This is the latest additional training program for rheumatology in the country. She continues to train young rheumatologists and do clinical research on osteoarthritis and the vasculitides.

Michihide Tokuhira - Invited Speaker

Michihide Tokuhira

Japan Community Health Care Organization Saitama Medical Center


1961 Born in Tokyo, Japan
1987 Graduated from Hiroshima medical school
1987- Resident, Keio University Hospital
2021- JCHO Saitama Medical Center

Xinping Tian - Invited Speaker

Xinping Tian

Peking Union Medical College Hospital


Chief physician of Rheumatology and Immunology Department in Peking University Union Hospital

Standing Committee of the Rheumatology Branch of the Chinese Medical Doctor Association

Chairman of vasculitis group of Rheumatology branch of Chinese Medical Doctor Association

Swee-Ping Tang - Chairperson

Swee-Ping Tang

Selayang Hospital


Dr. Tang Swee Ping is Senior Consultant Paediatrician and Paediatric Rheumatologist at the Selayang Hospital, Malaysia. She graduated from the University of Malaya, Kuala Lumpur and is a Fellow of the Royal College of Paediatrics and Child Health, UK . She was the first Paediatric Rheumatologist in the country and heads the only Paediatric Rheumatology tertiary referral center in Malaysia. Apart from clinical work, she is passionate on teaching junior doctors, leads the MRCPCH (UK) exams in Malaysia, keen in research and a member of the national ethics committee.

Eiichi Tanaka

Tokyo Women’s Medical University School of Medicine


The Japanese Society of Internal Medicine (Fellow of the Japanese Society of Internal Medicine)
The Japan College of Rheumatology (Board Certified Rheumatologist, Board Certified Rheumatologist Instructor)
The Japanese Society for Clinical Rheumatology and Related Research
The American College of Rheumatology

Clinical Science:
1. Administration and management of an observational cohort study in patients with rheumatoid arthritis (RA), the Institute of Rheumatology, Rheumatoid Arthritis (IORRA)
2. Epidemiological studies such as pharmacoeconomic analysis in patients with RA using IORRA database

Ma Hanna Monica Z Sollano - Invited Speaker

Ma Hanna Monica Z Sollano

Philippine Rheumatology Association


Dr. Sollano is a board-certified rheumatologist from the Philippines with special interests in osteoarthritis and vasculitis. She finished her medical studies at the University of Sto. Tomas and completed her residency and rheumatology fellowship training at Makati Medical Center.

Evelyn Salido - Invited Speaker

Evelyn Salido

University of the Philippines Manila


Dr. Evelyn Salido is a Professor of Rheumatology and the Head of the Division of Rheumatology, Department of Medicine, University of the Philippines-Philippine General Hospital in Manila. She was a past president of the Philippine Rheumatology Association. She is a member of the Gout SIG of the PRA and of the APLAR. She is author of several publications on gout, SLE, RA, pain, and vasculitis.

Muhammad Ahmed Saeed - Invited Speaker

Muhammad Ahmed Saeed

Central Park Medical College


Dr. Muhammad Ahmed Saeed is Professor and Head Department of Rheumatology at Central Park Teaching Hospital affiliated with Central Park Medical College, Lahore, Pakistan. He has been contributing extensively to teaching, training and research, in the field of Rheumatology for almost 17 years. He has co-authored 21 publications and has presented several abstracts at international as well as national conferences. He has special interest in epidemiology of rheumatic diseases, SpondyloArthritis, and Lupus.

He has served Pakistan society for Rheumatology (PSR) as General Secretary and Treasurer and is currently the Chair PSR Membership committee and the council member. He is also a Fellow of American College of Rheumatology and has been recipient of American College of Physicians International Fellowship Exchange Program award for 2014. He was awarded APLAR-COPCORD grant in 2018.
He is also actively involved in community service and is one of the founding board members and Co-Chair of Arthritis Care Foundation, a trust working for welfare of less privilege arthritis patients.

Blank Circle

Kenneth Saag

APLAR21-Placeholder (300x300)

Sponsor Name

Sponsor bio – Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.